

FINAL REPORT

Test Facility Study No. 5002034

A 6-Week (4 doses) Intramuscular Injection Toxicity Study of mRNA-1647 in Sprague-Dawley Rats Followed by a 2-Week Recovery Period

TEST FACILITY:
Charles River Laboratories Montreal ULC
Sherbrooke Site (CR SHB)
1580 Ida-Metivier
Sherbrooke, QC J1E 0Bs
Canada

TABLE OF CONTENTS

LIST OF FIGURES	6
LIST OF TABLES	ilans
LIST OF APPENDICES	di 8
OLIATITY A COLD ANCE OF A TEMPNIT	9
COMPLIANCE STATEMENT	11
1. RESPONSIBLE PERSONNEL	12
1.1. Test Facility	12
1.2. Individual Scientists (IS) at Test Facility	12
COMPLIANCE STATEMENT 1. RESPONSIBLE PERSONNEL 1.1. Test Facility 1.2. Individual Scientists (IS) at Test Facility 1.3. Principal Investigators (PI) at Test Facility-designated Test Site(s)	12
1.4. PIs at Sponsor or Sponsor-designated Test Site(s)	12
2. SUMMARY	13
3. INTRODUCTION	16
1.2. Individual Scientists (IS) at Test Facility 1.3. Principal Investigators (PI) at Test Facility-designated Test Site(s) 1.4. PIs at Sponsor or Sponsor-designated Test Site(s) 2. SUMMARY 3. INTRODUCTION 4. MATERIALS AND METHODS 4.1. Test Item 4.2. Reference Item 4.3. Test and Reference Item Characterization	16
4.1. Test Item	16
4.2. Reference Item	17
4.3. Test and Reference Item Characterization	17
4.4. Analysis of Test flem	17
4.5. Reserve Samples	17
4.6. Test and Reference Item Inventory and Disposition	17
4.7. Dose Formulation and Analysis	18
4.7.1. Preparation of Reference Item	18
4.7.2. Preparation of Test Item	18
4.7.3. Sample Collection and Analysis	18
4.7.3.1. Analytical Method	18
4.7.3.2. Concentration and Homogeneity Analysis	19
4.7.3.3. Stability Analysis	19
4.8. Test System	19

4.8.1. Receipt	19
4.8.2. Justification for Test System and Number of Animals	19
4.8.3. Animal Identification	19
4.8.4. Environmental Acclimation	20
4.8.5. Selection, Assignment, Replacement, and Disposition of Animals	20
4.8.6. Husbandry	7.0.
4.8.6.1. Housing	20
4.8.6.2. Environmental Conditions	20
4.8.6.3. Food	20
4.8.6.4. Water	21
4.8.6.1. Housing 4.8.6.2. Environmental Conditions 4.8.6.3. Food 4.8.6.4. Water 4.8.6.5. Animal Enrichment 4.8.6.6. Veterinary Care 4.9. Experimental Design 4.9.1. Administration of Test Materials 4.9.2. Justification of Route and Dose Levels 4.9.1. In-life Procedures Observations and Measurements	21
4.8.6.6. Veterinary Care	21
4.9. Experimental Design	21
4.9.1. Administration of Test Materials	22
4.9.2. Justification of Route and Dose Levels	22
4.10. In-life Procedures, Observations, and Measurements	22
4.10.1. Mortality/Moribundity Checks	22
4.10.2. Clinical Observations	22
4.10.2.1. Detailed Clinical Observations	22
4.10.3. Local Irritation Assessment	23
4.10.4. Body Weights	23
4.10.5. Food Consumption	23
4.10.6. Ophthalmic Examinations	23
4.10.7. Body Temperature	23
4.11. Laboratory Evaluations	24
4.11.1. Clinical Pathology	24
4.11.1.1 Sample Collection	24
4.11.1.2. Hematology	24
4.11.1.3. Coagulation	24

	4.11.1.4. Clinical Chemistry	25
	4.11.1.5. α1-acid Glycoprotein and α2-macroglobulin Analysis	25
	4.11.2. Laboratory Investigation (Cytokines Analysis)	25
	4.11.3. Anti-Therapeutic Antibody (ATA) Analysis	26
	4.12. PBMC Analysis	27
	4.13. Terminal Procedures	27
	4.13.1. Unscheduled Deaths	27
	4.13.2. Scheduled Euthanasia	27
	4.13.3. Necropsy	27
	4.13.4. Organ Weights	28
	4.13.5. Tissue Collection and Preservation	28
	4.13.6. Histology	29
	4.13.7. Histopathology	29
	4.13.8. Peer Review	29
	4.13.1. Unscheduled Deaths 4.13.2. Scheduled Euthanasia 4.13.3. Necropsy 4.13.4. Organ Weights 4.13.5. Tissue Collection and Preservation 4.13.6. Histology 4.13.7. Histopathology 4.13.8. Peer Review 4.13.9. Bone Marrow Smear Analysis 5. CONSTRUCTED VARIABLES 6. STATISTICAL ANALYSIS 6.1. Parametric/Non-parametric	30
5	CONSTRUCTED VARIABLES	30
6	5. STATISTICAL ANALYSIS	30
	6.1. Parametric/Non-parametric	31
7	COMPUTERIZED SYSTEMS	31
	B. RETENTION OF RECORDS, SAMPLES, AND SPECIMENS	32
9	RESULTS	33
	9.1. Dose Formulation Analyses	33
	9.2. End of Use Bulk Test Item Analysis	33
	9.3. Mortality	33
	9.4. Clinical Observations	33
16	9.5. Local Irritation Assessment	33
	9.6. Body Weights and Body Weight Gains	34
	9.7. Food Consumption	34
	9.8. Opthalmology	34
	THE PERSON NAMED IN COLUMN TO SERVICE AND ADDRESS OF THE PERSON NAMED IN COLUMN TO SE	

9.9. Body Temperature	34
9.10. Hematology	35
9.11. Coagulation	36
9.12. Clinical Chemistry	36
9.13. Alpha-1-Acid Glycoprotein	i 037
9.14. Alpha-2-Macroglobulin	37
9.15. Cytokines	37
9.16. Anti-Therapeutic Antibody (ATA)	37
9.17. PBMC	38
9.18. Gross Pathology	38
9.18.1. Terminal Necropsy (Day 44).	38
9.18.2. Recovery Necropsy (Day 57)	39
9.19. Organ Weights	40
9.19.1. Terminal Necropsy (Day 44)	40
9.19.2. Recovery Necropsy (Day 57)	40
9.20. Histopathology	41
9.20.1. Terminal Necropsy (Day 44)	41
9.20.2. Recovery Necropsy (Day 57)	43
9.14. Alpha-2-Macroglobulin 9.15. Cytokines 9.16. Anti-Therapeutic Antibody (ATA) 9.17. PBMC 9.18. Gross Pathology 9.18.1. Terminal Necropsy (Day 44) 9.18.2. Recovery Necropsy (Day 57) 9.19. Organ Weights 9.19.1. Terminal Necropsy (Day 57) 9.20. Histopathology 9.20.1. Terminal Necropsy (Day 44) 9.20.2. Recovery Necropsy (Day 58) 10. CONCLUSION	45

LIST OF TABLES

Table 1 Summary of Clinical Observations	48 Ker
Table 2 Summary of Body Weights	53
Table 3 Summary of Body Weight Gains	
Table 4 Summary of Food Consumption	61
rable 3 Summary of Body Temperature varies	05
Table 6 Summary of Hematology Values	67
Table 7 Summary of Coagulation Values	79
Table 4 Summary of Food Consumption Table 5 Summary of Body Temperature Values Table 6 Summary of Hematology Values Table 7 Summary of Coagulation Values Table 8 Summary of Clinical Chemistry Values	83
Table 6 Summary of Hematology Values Table 7 Summary of Coagulation Values Table 8 Summary of Clinical Chemistry Values Table 9 Summary of α1-acid Glycoprotein and α2-macroglobulin Values	95
Table 6 Summary of Coagulation Values Table 8 Summary of Clinical Chemistry Values Table 9 Summary of α1-acid Glycoprotein and α2-macroglobulin Values Table 10 Summary of Cytokine Values Table 10 Summary of Cytokine Values	99

LIST OF APPENDICES

	Appendix 1 Study Plan, Amendments, and Deviations	111
	Appendix 2 Test and Reference Item Characterization	345
	Appendix 3 Dose Formulation Analysis Report	354
	Appendix 4 Individual Animal Mortality	391
	Appendix 5 Individual Clinical Observations and Local Irritation Assessment	395
	Appendix 6 Individual Body Weights	449
	Appendix 7 Individual Body Weight Gains	466
	Appendix 8 Individual Food Consumption Values	483
	Appendix 9 Body Temperature	500
	Appendix 10 Individual Hematology Values	509
	Appendix 11 Individual Coagulation Values	537
	Appendix 12 Individual Clinical Chemistry Values	545
	Appendix 3 Dose Formulation Analysis Report Appendix 4 Individual Animal Mortality	566
	Appendix 14 Individual Cytokine Values	577
	Appendix 14 Individual Cytokine Values	586
	Appendix 16 Anti-Therapeutic Antibody Report	603
	Appendix 17 PBMC Report	630
	Appendix 18 Immunology Report	648
	Appendix 19 Pathology Report	705
	Appendix 20 Pathology Peer Review Statement	1015
This docu	ment cannot be Re	

QUALITY ASSURANCE STATEMENT

Study Number: 5002034

This Study has been audited by Quality Assurance in accordance with the applicable Good Laboratory Practice regulations. Reports were submitted in accordance with SOPs as follows:

QA INSPECTION DATES

Dates Findings Submitted to:

Date(s) of Audit	Phase(s) Audited	Study Director	Management
09-Mar-2017	Final Study Plan	10-Mar-2017	10-Mar-2017
20-Mar-2017	Study Plan Amendment 1	20-Mar-2017	20-Mar-2017
23-Mar-2017	Addition of Study Plan to Provantis	23-Mar-2017	23-Mar-2017
23-Mar-2017	Study Plan Amendment 2	23-Mar-2017	23-Mar-2017
05-Apr-2017	Dose Preparation	05-Apr-2017	05-Apr-2017
06-Apr-2017	Draize Evaluation	06-Apr-2017	06-Apr-2017
18-Apr-2017	Study Plan Amendment 3	18-Apr-2017	18-Apr-2017
04-May-2017	Necropsy Necropsy	04-May-2017	04-May-2017
05-May-2017	Study Plan Amendment 4	05-May-2017	05-May-2017
11-May-2017	Biochemistry	11-May-2017	11-May-2017
22-Jun-2017	Data Review Veterinary Services	30-Jun-2017	30-Jun-2017
23-Jun-2017	Data Review Animal Care	30-Jun-2017	30-Jun-2017
23-Jun-2017 - 27-Jun-2017	Data Review - Technical Operations	30-Jun-2017	30-Jun-2017
27-Jun-2017	Data Review - Formulations	30-Jun-2017	30-Jun-2017
27-Jun-2017 - 28-Jun-2017	Data Review - Clinical Pathology	30-Jun-2017	30-Jun-2017
27-Jun-2017	Data Review - Technical Operations	30-Jun-2017	30-Jun-2017
28-Jun-2017	Study Plan Amendment 5	28-Jun-2017	28-Jun-2017
28-Jun-2017 28-Jun-2017	Data Review - Shipping/Receiving	30-Jun-2017	30-Jun-2017
28-Jun-2017 S	Report Preparation	30-Jun-2017	30-Jun-2017
28-Jun-2017	Data Review - Necropsy	30-Jun-2017	30-Jun-2017
28-Jun-2017 - 29-Jun-2017	Data Review - Histology	30-Jun-2017	30-Jun-2017
29-Jun-2017	Draft Phase Report - Ophthalmology	30-Jun-2017	30-Jun-2017
29-Jun-2017 - 30-Jun-2017	Draft Report - Materials and Methods	30-Jun-2017	30-Jun-2017
29-Jun-2017	Report Preparation	30-Jun-2017	30-Jun-2017
29-Jun-2017	Data Review - Shipping/Receiving	30-Jun-2017	30-Jun-2017
25-Aug-2017 - 26-Aug-2017	Final Report	28-Aug-2017	28-Aug-2017
29-Aug-2017 31-Aug-2017 - 01-Sep-2017	Data Review - Analytical Chemistry	01-Sep-2017	01-Sep-2017
29-Aug-2017 31-Aug-2017 - 01-Sep-2017	Draft Phase Report - Dose Formulation Analysis	01-Sep-2017	01-Sep-2017
18-Sep-2017	Study Plan Amendment 6	18-Sep-2017	18-Sep-2017

QUALITY ASSURANCE STATEMENT - Study Number: 5002034

QA INSPECTION DATES

Dates Findings Submitted to:

Date(s) of Audit	Phase(s) Audited	Study Director	Study Director Management
25-Sep-2017	Final Report	26-Sep-2017	26-Sep-2017

In addition to the above-mentioned audits, process-based and/or routine facility inspections were also conducted during the course of this study. Inspection findings, if any, specific to this study were reported by Quality Assurance to the Study Director and Management and listed as a Phase Audit on this Quality Assurance Statement.

The Final Report has been reviewed to assure that it accurately describes the materials and methods, and that

escribes the material and a physical dependent of the period of the peri **Quality Assurance Auditor**

Date

5002034 Qas

COMPLIANCE STATEMENT

The study was performed in accordance with the OECD Principles of Good Laboratory Practice and as accepted by Regulatory Authorities throughout the European Union, United States of America (FDA), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement.


Any portion of this study conducted in the USA was performed in accordance with the U.S. Department of Health and Human Services, Food and Drug Administration. United States Code of Federal Regulations, Title 21, Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies and as accepted by Regulatory Authorities throughout the European Union (OECD Principles of Good Laboratory Practice), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement.

Exceptions from the above regulations are listed below.

- Characterization of the Test Item was performed by the Sponsor or Sponsor subcontractor
 according to established SOPs, controls, and approved test methodologies to ensure integrity
 and validity of the results generated; these analyses were not conducted in compliance with
 the GLP or GMP regulations.
- Analysis of cytokines, α2-macroglobulin, α1-acid glycoprotein, anti-therapeutic antibody and PBMCs were conducted using scientifically qualified methods and in accordance with all applicable analytical procedures.
- The purity analysis of the bulk test item was conducted using a scientifically qualified methods and in accordance with applicable analytical procedures.
- Pathology peer review.

This study was conducted in accordance with the procedures described herein. All deviations authorized/acknowledged by the Study Director are documented in the Study Records. The report represents an accurate and complete record of the results obtained.

There were no deviations from the above regulations that affected the overall integrity of the study or the interpretation of the study results and conclusions.



1. RESPONSIBLE PERSONNEL

1.1. Test Facility

Study Director

Test Facility Management

BSc BSc

1.2. Individual Scientists (IS) at Test Facility

Ophthalmology

DMV, MS, DACVO Consultant Ophthalmologist

Analytical Chemistry (Concentration, and Particle size and Purity Analysis) BSc Charles River Laboratories Montreal ULC Senneville, QC, Canada

Immunology (Cytokine, Alpha-2 Macroglobulin and Alpha-1 Glycoprotein Analysis)

MSc

Charles River Laboratories Montreal ULC Sherbooke, QC, Canada

1.3. Principal Investigators (PI) at Test Facility-designated Test Site(s)

Pathology

DVM, DACVP, DABT Charles River Laboratories, Inc. Durham, NC, USA

1.4. PIs at Sponsor or Sponsor-designated Test Site(s)

Anti-Therapeutic Antibody Analysis

Integrated BioTherapeutics, Inc. Rockville, MD, USA

PBMC Analysis

Southern Research Birmingham, AL, USA

SUMMARY

a Valiations thereof The objectives of this study were to determine the potential toxicity of mRNA 1647, when given by intramuscular injection for 6 weeks (4 doses) to rats and to evaluate the potential reversibility of any findings following a 2-week recovery period.

The study design was as follows:

Text Table 1 **Experimental Design**

		Dose	Dose	Dose		imals	is _s	
Group	Test	Levela	Volume	Concentration ^a	Main S	Study	Recove	ry Study
No.	Material	(µg/dose)	(µL/dose)	(mg/mL)	Males	Females	Males	Females
1	Reference Item	0	200	0	10	10	23	5
2	mRNA- 1647	10/8.9	200	0.05/0.045	10	2/10/01	_	-
3	mRNA- 1647	30/27	200	0.15/0.14	10 0	010	-	-
4	mRNA- 1647	100/89	200	0.5/0.45	(C)10 S	10	5	5

^{- :} Not applicable

The following parameters and endpoints were evaluated in this study: clinical observations consisting of twice daily examinations for mortality/moribundity and weekly detailed examinations; local irritation assessment at least 24- and 72-hour postdose on dosing days and weekly when there were no dosing and during the recovery period; weekly body weights and food consumption measurements; ophthalmic examinations once prior to dosing initiation and during Day 40 (males) or Day 39 (females) of the dosing period; body temperature on Days 1 and 43 at predose and 6 and 24 hours postdose (end of each group); clinical pathology assessment (hematology, coagulation, clinical chemistry, α1-acid glycoprotein and α2-macroglobulin) at termination; cytokine analysis (IL-1β, IL-6, TNF-α, IP-10, MIP-1-α and MCP-1) on Days 1, 15, 29 and 43 at 6 hours postdose and on Day 57; Anti-Therapeutic Antibody (ATA) analysis prior to dosing initiation, on Day 29 (predose), on Day 43 (postdose) and on Day 57; PBMC analysis on Day 44; gross necropsy findings, organ weights, and histopathologic examinations.

There were no mRNA-1647-related changes in food consumption and ophthalmology.

There were no mRNA-1647-related mortalities during the course of the study. One male given the Reference Item (PBS) was found dead on Day 43. The pathological evaluation revealed gross abnormal findings in the adrenal gland, kidneys, thymus; and lungs. Histopathology findings for this control male were incidental and did not explain the cause of death.

mRNA-1647-treated main study and recovery animals had significant detectable antibody responses against CMV gB protein and CMV gH pentamer complex.

Values based on Summary of Analysis (SoA) issued on 16 Mar 2017 / Values based on SoA issued on 31 May 2017 (Refer to memorandum in Appendix 2).

mRNA-1647 elicited both CD4 and CD8 T cell responses to both CMV Pentamer and gB. T cell response (PBMC analysis) were significantly variable within each test group with data trending towards higher T cells responses at higher doses of mRNA-1647.

The primary mRNA-1647-related findings were observed at the site of injection. At all doses, increase in incidence and/or severity with dose of very slight to severe edema was noted at the injection site, following dosing of males and females (peaking 24 hours postdose, generally x decreasing by 72 hours postdose). Although sporadic in occurrences, slight to moderately severe erythema was noted as well, but was only considered mRNA-1647-related at 89 µg/dose. Swelling (soft or firm), noted on the injection site following the third and/or fourth doses, together with localized skin redness at the injection site noted throughout the dosing period, were consistent with the edema and erythema findings. Macroscopically, dose-dependent firm abnormal consistency, dark foci and/or swelling at the injection site correlated with microscopic changes observed at all doses that included minimal to moderate mixed cell inflammation involving the subcutaneous tissues, skeletal muscle, and to a lesser extent the dermis, as well as minimal to moderate subcutaneous edema. Increased incidence and/or severity of minimal to marked mixed cell inflammation was seen in the popliteal and/or inguinal lymph nodes (draining) of all animals at $\geq 8.9 \,\mu\text{g/dose}$ which correlated macroscopically with enlargement; minimal to marked mixed cell inflammation was frequently observed in the perineurial tissue surrounding the sciatic nerve of animals given $\geq 8.9 \,\mu\text{g/dose}$. Sciatic nerve and lymph node inflammatory changes were regarded as secondary to the injection site inflammation. mRNA-1647-related microscopic findings were still noted at the injection site and sciatic nerve of recovery animals; minimal to mild mononuclear cell infiltration and minimal mixed cell inflammation were seen respectively in the injection site and on the sciatic nerves of males and/or females given 89 µg/dose. The absence of mixed cell inflammation and edema, with a shift to minimal to mild mononuclear cell infiltration, at the intramuscular injections sites and a reduced incidence and/or severity of perineurial mixed cell inflammation associated with the sciatic nerves were however all indicative of a partial recovery. Clinical signs (i.e. edema, swelling, erythema and reddening of the skin) observed at the injection site and gross pathology findings as well as microscopic findings observed at the inguinal and popliteal lymph nodes were no longer observed in recovery animals, indicating a complete recovery for these changes.

mRNA-1647-related systemic changes associated with inflammation were also observed in animals given $\geq 27~\mu g/dose$ and included minimally increased hematopoiesis of the myeloid lineage in the bone marrow. This change was likely a reactive response to the pronounced inflammation observed at the injection site. Other systemic findings included increases in absolute and/or relative spleen weights without correlating histopathology, and minimal to mild decreased cellularity of the splenic periarteriolar lymphoid sheath. Clinical pathology changes suggestive of inflammation were also observed in males and/or females given mRNA-1647 at all doses (unless noted otherwise) and included: minimal to moderate increases in neutrophil, eosinophil and large unstained cell counts with concomitant increases in white blood cell counts, minimal decreases in lymphocyte counts and platelet counts (females at 89 $\mu g/dose$), minimal increases in activated partial thromboplastin time and mild increases in fibrinogen, minimal increases in globulin, minimal decreases in albumin, with concomitant decreases in A/G ratio. Increase in body temperature postdose (89 $\mu g/dose$), along with increases in acute phase protein Alpha-1-Glycoprotein and Alpha-2-Macroglobulin and elevations of cytokine levels IP-10

(89 μg/dose) and MCP-1, were all suggestive of inflammation. At the end of the 2-week recovery period, Alpha-2-Macroglobulin levels were still higher than controls, but to a lesser extent, the incidence and severity of increased absolute and/or relative spleen weights was reduced, as well as the decrease in cellularity of the periarteriolar lymphoid sheath in the spleen, suggesting only a partial recovery for these aforementioned findings. All other mRNA-1647-related systemic changes returned close to control values and, as such, were considered fully recovered.

When compared to controls, following each dose, a tendency towards lower mean body weight gains was noted in males given $\geq 8.9~\mu g/dose$ and in females given $89~\mu g/dose$; these changes sometimes reached statistical significance. The changes were only cumulative in males. There were no clear association of the body weight changes with food consumption or clinical observations. The body weight changes were generally comparable or rebounded during the 2-week recovery period.

In conclusion, administration of mRNA-1647 by intramuscular injection for 6 weeks (4 doses) was clinically well tolerated (no mortality, major decreases in body weight and no changes in food consumption or deleterious changes in hematology, coagulation or clinical chemistry parameters) in rats up to 89 µg/dose. Starting at 8.9 µg/dose, generally dose-dependent changes in clinical signs at the injection site, clinical pathology parameters, cytokines and acute protein levels were consistent with an inflammatory response at the injection site. Dose-related target the secovery period and the leaded and the land that had been a supported to the land that the land the land that had the land the land that had the land that had the land that had the land the land that had th organ effects were limited to the injection site, the bone marrow, the inguinal and popliteal lymph nodes, the connective tissue surrounding the sciatic nerve and the spleen of animals given mRNA-1647. At the end of the 2-week recovery period, all changes were partially or fully

3. INTRODUCTION

The objectives of this study were to determine the potential toxicity of mRNA 1647, when given by intramuscular injection for 6 weeks (4 doses) to rats and to evaluate the potential reversibility of any findings following a 2-week recovery period.

The design of this study is based on the study objectives, the overall product development strategy for the Test Item, and the following study design guidelines:

- OECD Guideline 407. Repeated Dose 28-day Oral Toxicity Study in Rodents.
- Committee for Medicinal Products for Human Use (CHMP). Note for Guidance on Repeated Dose Toxicity. CPMP/SWP/1042/99corr.
- ICH Harmonised Tripartite Guideline M3 (R2). Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.
- Japanese Guidelines for Nonclinical Studies of Drugs Manual (1995). Guidelines for Toxicity Studies of Drugs (Chapter 3, Repeated Dose Toxicity Studies).
- Appendix to Director General Notification, No. 12-Nousan-8147, 24 Nov 2000, Agricultural Production Bureau, Ministry of Agriculture, Forestry and Fisheries of Japan (JMAFF).

The Study Director signed the study plan on 08 Mar 2017, and dosing was initiated on 22 Mar 2017 (males) and on 23 Mar 2017 (females). The in-life phase of the study was completed on 05 May 2017 (main study animals) and on 18 May 2017 (recovery study animals), the date of the last necropsy. The experimental start date was 08 Mar 2017, and the experimental completion date is 20 Sep 2017 (signature of the pathology report). The study plan, study plan amendments, and deviations are presented in Appendix 1.

4. MATERIALS AND METHODS

4.1. Test Item

Identification: mRNA-1647

Batch (Lot) No.: MTDP17015

Retest Date: An end-of-use analysis of the bulk Test Item was performed to

demonstrate the stability of the Test Item during the dosing period.

Physical Description: White to off-white lipid nanoparticle dispersion

Concentration: 2.7 / 2.4*mg/mL

Storage Conditions: Kept in a freezer set to maintain -20°C

Supplier: Moderna Therapeutics, Inc

^{*} Concentration based on SoA released on 16 Mar 2017 / Concentration based on SoA released on 31 May 2017

4.2. Reference Item

Identification: Phosphate-buffered Saline (PBS) pH 7.2

Batch (Lot) No.: 1809319

1854892 1759866 1830677

Expiration Date: Jul 2018

Dec 2018 Feb 2018 Sep 2018

Physical Description: Liquid

Storage Conditions: Kept in a controlled temperature area set to maintain 21°C

4.3. Test and Reference Item Characterization

The Sponsor provided to the Test Facility documentation of the identity, strength, purity, composition, and stability for the Test Item. A Summary of Analysis was provided to the Test Facility and is presented in Appendix 2.

4.4. Analysis of Test Item

A sample (2 vials) of the Test Item were taken on the completion of the dosing period. Analysis of bulk Test Item for concentration, particle size and purity were performed.

The first vial was transferred (on dry ice) to the analytical laboratory at the Test Facility for concentration and particle size analysis.

The second vial was transferred (on dry ice) to the analytical laboratory at the Test Facility for purity analysis.

Concentration, Purity and Particle size analysis were performed by IEX- HPLC, Differential Light Scattering (DLS) and rHPLC using validated or qualified analytical procedures.

4.5. Reserve Samples

For each batch (lot) of Test and Reference Items, a reserve sample (1 mL or 1 vial) was collected and maintained under the appropriate storage conditions by the Test Facility (refer to Appendix 1 for one exception).

4.6. Test and Reference Item Inventory and Disposition

Records of the receipt, distribution, and storage and disposition of Test and Reference Items were maintained. With the exception of reserve samples, all unused Test and Reference Items were returned to the Sponsor after completion of dosing.

4.7. Dose Formulation and Analysis

(Appendix 3)

4.7.1. Preparation of Reference Item

Dose formulation preparations were performed under a laminar flow hood using clean procedures.

The Reference Item, Phosphate-buffered Saline (PBS) pH 7.2, was dispensed on days of dosing (i.e. Days 1, 15, 29 and 43) for administration to Group 1 control animals and was used as required to dilute the bulk Test Item for administration to Groups 2 to 4 animals. The aliquots were stored in a refrigerator set to maintain 4°C until use. They were removed from the refrigerator and allowed to warm to room temperature for at least 30 minutes before dosing.

Details of the preparation and dispensing of the Reference Item have been retained in the Study Records.

4.7.2. Preparation of Test Item

Dose formulation preparations were performed under a laminar flow hood using clean procedures.

Test Item formulations were diluted with PBS pH 7.2, as necessary for administration. The dosing formulations were prepared on each days of dosing (i.e. Days 1, 15, 29 and 43) and were stored in a refrigerator set to maintain 4°C. The dose formulations were allowed to warm to room temperature for at least 30 minutes prior to dosing. Stock vials were used only once.

Empty vials were discarded. Any residual volumes of formulated Test Item and stock Test Item were stored in a refrigerator set at 4°C and were discarded prior to report finalization.

4.7.3. Sample Collection and Analysis

Dose formulation samples were collected for analysis as indicated in Text Table 2.

Text Table 2

Dose Formulation Sample Collection Schedule

Interval	Homogeneity	Concentration	Sampling From
Day 1	All groups ^a	All groups	Dosing container
Day 43	N/A	All groups	Dosing container

N/A = Not applicable.

Samples to be analyzed were transferred on ice pack to the analytical laboratory.

4.7.3.1. Analytical Method

Analyses described below were performed by IEX-HPLC using a validated analytical procedure (CR-MTL Study No.1802050).

^a The homogeneity results obtained from the top, middle and bottom preparations were averaged and utilized as the concentration results.

b Samples were collected on the first preparation of the study and on the last preparation of the study.

4.7.3.2. Concentration and Homogeneity Analysis

On Days 1 and 43 of the study, duplicate sets of samples (0.5 mL) were sent to the analytical laboratory; triplicate set of samples (0.5 mL) were retained at the Test Facility as backup samples. Samples were collected in an appropriate sized glass container from the top, middle and bottom strata of the dosing container for each concentration except for Group 1 dosing formulation and on day 43 where only concentration analysis were required; the formulation was then only sampled from the middle stratum.

Concentration results were considered acceptable if mean sample concentration results were within or equal to \pm 15% of theoretical concentration. Each individual sample concentration result was considered acceptable if it was within or equal to \pm 20%. After acceptance of the analytical results, backup samples were discarded.

Homogeneity results were considered acceptable if the relative standard deviation (RSD) of the mean value at each sampling location was $\leq 5\%$.

After acceptance of the analytical results, backup samples were discarded.

4.7.3.3. Stability Analysis

There was no stability analysis performed for concentration used on this study however, end of use stability analysis of the bulk test item was performed at the end of the dosing period.

4.8. Test System

4.8.1. Receipt

On 08 March 2017, one hundred and twenty Crl:CD(SD) Sprague-Dawley rat (60 males and 60 females) were received from Charles River Canada Inc., St. Constant, QC, Canada. The animals were 08 weeks old and males weighed between 235 and 297 grams and females weighed between 195 and 248 grams at initiation of dosing.

4.8.2. Justification for Test System and Number of Animals

The Sprague Dawley rat was chosen as the animal model for this study as it is an accepted rodent species for preclinical toxicity testing by regulatory agencies.

The total number of animals to be used in this study was considered to be the minimum required to properly characterize the effects of the Test Item. This study has been designed such that it does not require an unnecessary number of animals to accomplish its objectives.

At this time, studies in laboratory animals provide the best available basis for extrapolation to humans and are required to support regulatory submissions. Acceptable models which do not use live animals currently do not exist.

4.8.3. Animal Identification

Each animal was identified using a subcutaneously implanted electronic identification chip.

4.8.4. Environmental Acclimation

A minimum acclimation period of 14 days was allowed between animal receipt and the start of dosing in order to accustom the animals to the laboratory environment (refer to Appendix 1).

4.8.5. Selection, Assignment, Replacement, and Disposition of Animals

Animals were assigned to groups by a stratified randomization scheme designed to achieve similar group mean body weights. Males and females were randomized separately. Animals in poor health or at extremes of body weight range were not assigned to groups.

Before the initiation of dosing, assigned animals with compromising background ophthalmic findings, that were considered unsuitable for use in the study, were replaced by alternate animals obtained from the same shipment and maintained under the same environmental conditions.

The alternate animals were used as replacements on the study within approximately 4 days.

4.8.6. Husbandry

4.8.6.1. Housing

Animals were group housed (up to 3 animals of the same sex and same dosing group together) in polycarbonate cages containing appropriate bedding equipped with an automatic watering valve. These housing conditions were maintained all along the study. The rooms in which the animals were kept was documented in the study records.

Animals were separated during designated procedures/activities. Each cage was clearly labeled with a color-coded cage card indicating study, group, animal number(s), and sex. Cages were arranged on the racks in group order. Control group animals were housed on a separate rack from the Test Item-dosed animals.

4.8.6.2. Environmental Conditions

Target temperatures of 19°C to 25°C with a relative target humidity of 30% to 70% were maintained. A 12-hour light/12-hour dark cycle was maintained, except when interrupted for designated procedures.

4.8.6.3. Food

PMI Nutrition International Certified Rodent Chow No. 5CR4 (14% protein) was provided ad libitum throughout the study, except during designated procedures. The same diet in meal form was provided to one female animal from Group 4 as warranted by clinical signs (broken/damaged incisors). On few occasions, wet pellets were also provided to Group 4 animals as warranted by clinical signs.

The feed was analyzed by the supplier for nutritional components and environmental contaminants. Results of the analysis are provided by the supplier and are on file at the Test Facility.

It is considered that there are no known contaminants in the feed that would interfere with the objectives of the study.

4.8.6.4. Water

Municipal tap water after treatment by reverse osmosis and ultraviolet irradiation was freely available to each animal via an automatic watering system (except during designated procedures).

Periodic analysis of the water is performed, and results of these analyses are on file at the Test Facility.

It is considered that there are no known contaminants in the water that could interfere with the outcome of the study.

4.8.6.5. Animal Enrichment

Animals were socially housed for psychological/environmental enrichment and were provided with items such as a hiding device and a chewing object, except when interrupted by study procedures/activities.

4.8.6.6. Veterinary Care

Veterinary care was available throughout the course of the study, and animals were examined by the veterinary staff as warranted by clinical signs or other changes. All veterinary examinations were documented in the study records. No veterinary treatments were necessary during the course of the study.

Reaction (Skin scab) to non-toxic pen used for marking the injection area was observed for control Animals Nos. 1510 and 1514 on Day 21 and 38, respectively. Consequently, no marking of the injection site was performed for these animals after that day.

4.9. Experimental Design

Text Table 3
Experimental Design

		Dose	ODose	Dose	Animals No.			
Group	Test	Level ^a	Volume	olume Concentration ^a Main Study Recovery Study		Main Study Reco		ry Study
No.	Material	(μg/dose)	(µL/dose)	(mg/mL)	Males	Females	Males	Females
		12, 11,						1511,
1	Reference	2500 O	200	0	1001-	1501-	1011-	1612,
1	ltem	250 0	200	0	1010	1510	1015	1513-
	113 16							1515
	" 100 So				2001,			
2	mRNA-	10/8.9	200	0.05/0.045	2102,	2501-		
2	1647	10/8.9	200	0.03/0.043	2003-	2510	_	-
" Co.					2010			
CUL					3001,	3501-		
100	mRNA-				3002,	3503,		
3	1647	30/27	200	0.15/0.14	3103,	3604,	_	-
	1047				3004-	3505-		
					3010	3510		
4	mRNA-	100/89	200	0.5/0.45	4001-	4501-	4011-	4511-
4	1647	100/69	200	0.5/0.45	4010	4510	4015	4515

^{- :} Not applicable

^a Values based on SoA issued on 16 Mar 2017 / Values based on SoA issued on 31 May 2017.

Prior to the start of dosing, animals were rejected from the study due to compromising background ophthalmic findings and were replaced with spare animals. The final allocation of animals is listed under Text Table 3. All animals remaining unassigned to groups after Day 4

The Test and Reference Items were administered to the appropriate animals via intramuscular injection into the lateral compartment of the thigh on Days 1, 15, 29 and 43, the injection was alternated on each dosing occasion (site 1= left site 2 was administered using a crui designated as Day 1.

The injection area was marked as frequently as required to allow appropriate visualization of administration sites (refer to Section 4.8.6.6 for exceptions). Hair may have been clipped or shaved, if required, to improve visualization of the injection sites. The injection site was documented in the raw data for each dose administered.

4.9.2. Justification of Route and Dose Levels

The intramuscular route of exposure was selected because this is the intended route of human exposure.

The dose levels for this toxicology study were chosen to approximate a substantial multiple of the anticipated clinical starting dose and top clinical dose. The highest dose to be tested was expected to represent the intended maximum human clinical dose and volume and was administered by the clinical route (intranuscular). At this dose level, minimal systemic toxicity was expected, but it was possible mild to moderate injection site reaction (redness, swelling) and potentially elevation of systemic cytokine/acute phase markers may have been observed. The mid- and low-dose were selected to evaluate the dose-dependent effect of this compound.

4.10. In-life Procedures, Observations, and Measurements

4.10.1. Mortality/Moribundity Checks

Throughout the study, animals were observed for general health/mortality and moribundity twice daily, once in the morning and once in the afternoon. Animals were not removed from cage during observation, unless necessary for identification or confirmation of possible findings.

4.10.2. Clinical Observations

4.10.2.1. Detailed Clinical Observations

The animals were removed from the cage, and a detailed clinical observation was performed weekly during the dosing and recovery periods, beginning during Week -1.

4.10.3. Local Irritation Assessment

On days of dosing and at least 24 and 72 hours postdose (end of each group), all animals had the dose injection site examined for signs of erythema/edema. Examinations were also performed weekly when there was no dosing and during the recovery period. Following Day 43 dosing, no assessment was performed on Main Study animals at 72 hours postdose as these animals were sent to necropsy on Day 44.

Observations were scored according to the Local Irritation Assessment scoring table as follows:

Erythema (Redness)	Score
No erythema	0 5
Very slight erythema (barely perceptible)	1 .:(0)
Mild erythema	2
Moderate to severe erythema	3
Severe erythema (beet redness to slight eschar formation, injury in depth)	4
Notable dermal lesion (maximized)	M
Edema (Swelling)	
No edema	0
Very slight edema (barely perceptible)	1
Slight edema	2
Moderate edema	3
Severe edema	4

4.10.4. Body Weights

4.10.4. Body Weights

Animals were weighed individually weekly, starting during Day -1. A fasted weight was recorded on the day of necropsy. Terminal body weight was not collected from animals found dead.

4.10.5. Food Consumption

Food consumption was quantitatively measured starting on Day -9 and weekly throughout the dosing and recovery periods (refer to Appendix 1 for additional details).

4.10.6. Ophthalmic Examinations

Animals had funduscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examinations once prior to dosing (all animals) and on Day 40 for males and Day 39 for females. As there were no Test Item-related ophthalmoscopic findings at the end of the dosing period, examinations were not performed during the recovery phase. The mydriatic used was atropine 0.126%.

4.10.7. Body Temperature

Rectal body temperature was recorded on un-sedated animals on Days 1 and 43 at predose and 6 and 24 hours postdose (end of each group). After first dose administration, body temperature of Group 4 female animals was monitored until 48 post dose, after which body temperature normal range (36.0°C to 38.0°C) was recovered.

4.11. Laboratory Evaluations

4.11.1. Clinical Pathology

4.11.1.1. Sample Collection

Blood was collected from the abdominal aorta following isoflurane anesthesia. After collection, samples were transferred to the appropriate laboratory for processing.

Animals were fasted overnight before blood sampling (for clinical chemistry). Samples were collected according to Text Table 4.

Text Table 4 Samples for Clinical Pathology Evaluation

Group Nos.	ıp Nos. Time Point		Hematology Coagulation		α1-acid glycoprotein/ α2-macroglobulin
1 to 4 ^a	Day 44	X	X	X NO	X
1 and 4	Day 57	X	X	O, XO,	X

X = Sample collected

4.11.1.2. Hematology

Blood samples (target volume of 0.5 mL collected in a tube containing EDTA as anticoagulant) were analyzed for the parameters specified in Text Table 5.

Text Table 5 Hematology Parameters

0, 10	7
Red blood cell count	
Hemoglobin concentration	White blood cell count
Hematocrit	Neutrophil count (absolute)
Mean corpuscular volume	Lymphocyte count (absolute)
Red Blood Cell Distribution Width	Monocyte count (absolute)
Mean corpuscular hemoglobin concentration	Eosinophil count (absolute)
Mean corpuscular hemoglobin	Basophil count (absolute)
Reticulocyte count (absolute)	Large unstained cells (absolute)
Platelet count	

A blood smear was prepared from each hematology sample. Blood smears were labeled, stained, and stored. Blood smears were read to investigate results for some animals.

4.11.1.3. Coagulation

ampl auticoagulant Text Table 6. Blood samples (target volume of 1.2 mL collected in a 1.3 mL tube containing citrate as anticoagulant) were processed for plasma, and plasma was analyzed for the parameters listed in

Text Table 6 **Coagulation Parameters**

Activated partial thromboplastin time	Prothrombin time		
Fibrinogen	Sample Quality		

Samples were only collected from those animals scheduled for euthanasia on Day 44.

4.11.1.4. Clinical Chemistry

Blood samples (target volume of 0.7 mL collected in serum separator tubes) were processed for serum, and the serum was analyzed for the parameters specified in Text Table 7.

Text Table 7 Clinical Chemistry Parameters

Alanine aminotransferase	Total protein
Aspartate aminotransferase	Albumin
Alkaline phosphatase	Globulin
Gamma-glutamyltransferase	Albumin/globulin ratio
Creatine Kinase	Glucose
Total bilirubin	Cholesterol
Urea nitrogen	Triglycerides
Creatinine	Sodium
Calcium	Potassium
Phosphorus	Chloride
	Sample Quality

4.11.1.5.α1-acid Glycoprotein and α2-macroglobulin Analysis

Blood (target volume of 0.7 mL collected in a serum separator tube) was obtained via abdominal aorta following isoflurane anesthesia before scheduled necropsy for all animals.

Blood samples were allowed to clot at ambient room temperature, until centrifugation which was carried out as soon as practical. The samples were centrifuged for 10 minutes in a refrigerated centrifuge (set to maintain 4°C) at 2400 g. Samples were processed to serum by the Immunology Department. Serum were aliquoted into 1 x 75 μ L aliquot for α 2-macroglobulin and 2 x 75 μ L aliquot and a leftover (when available) for α 1-acid glycoprotein. All samples were stored in a freezer set to maintain -20°C, pending analysis.

Analysis for α 1-acid glycoprotein and α 2-macroglobulin was conducted using a qualified ELISA method by the Immunology Department. The procedure to be followed along with the assay acceptance criteria was detailed in the appropriate analytical procedure.

Samples were analyzed in duplicate. Any residual/retained samples were discarded prior to report finalization.

4.11.2. Laboratory Investigation (Cytokines Analysis)

Blood was collected from the jugular vein of recovery animals. After collection, blood samples for serum were allowed to clot at ambient room temperature and blood samples for plasma were transferred on wet ice to the appropriate laboratory for processing.

Text Table 8 Sample Collection Schedule

Target Blood Volume (mL)			0.5	0.5				
	Anticoagulant		Anticoagulant None (SST) (refer to Appendix 1 for one exception)		(refer to Appendix 1 for	EDTA		
Ce	ntrifugat	ion setting		21105				
	Timep	oints		Sample Type				
Day Hrs Hemales No.			IFN-α*	IL-1β, IL-6, TNF-α, IP-10, MIP-1-α, MCP-1				
1	1 6 1011-1015,		X	X				
15	6	4011-4015	X	X				
29	6	1511 1610	X	XOTOL				
43	6	1511, 1612, 1513-1515,	X	X				
57	N/A	4511-4515	X	No Xioc				
	Mat	rix	Serum	Plasma				
V	Volume per aliquot (µL) Number of aliquot(s) Storage condition (set to maintain)		all volume	Sall volume				
N			1	1 1				
1			-80°C	-80°C				
	Responsi	ble Lab	CR-SHB	CR-SHB				

X = Sample collected; N/A = not applicable

The samples were analyzed by the Immunology department. Analysis for IL-1β, IL-6, TNF-α, IP-10, MIP-1-α and MCP-1 were conducted using a multiplex Luminex method. The procedures to be followed during the course of this study along with the assays acceptance criteria were detailed in the appropriate analytical procedure. Samples were analyzed in duplicate.

An Immunology Report for cytokine analysis is included as an appendix to the Final Report.

4.11.3. Anti-Therapeutic Antibody (ATA) Analysis

Before the initiation of dosing, on Day 29 (before dose administration, all animals), on Day 43 (post dose administration, main animals only) and on Day 57 (recovery animals), target blood volume of 0.5 mL was collected in a serum separator tube by jugular venipuncture from the appropriate animals.

Samples were mixed gently and allowed to clot at ambient room temperature until centrifugation, which was carried out as soon as practical. The samples were centrifuged for 10 minutes in a refrigerated centrifuge (set to maintain 4°C) at 1200 g. The resultant serum was separated, transferred to uniquely labeled clear polypropylene tubes, frozen immediately over dry ice and transferred to a freezer set to maintain -80°C until shipment on dry ice to Integrated BioTherapeutics, Inc., Rockville, MA, USA for analysis.

The samples were analyzed for rat anti-CMV antibodies using a qualified ELISA method.

An Anti-therapeutic Antibody Report is included as an appendix to the Final Report.

^{*} The assay validation of IFN-α did not work appropriately and serum samples analysis was not conducted.

4.12. PBMC Analysis

On Day 44, blood (target volume of 0.5 mL collected in a tube containing Sodium Heparin as Samples were analyzed using a qualified method.

An Immunology Report for PBMC analysis is included as an appendix to the Final Report.

4.13. Terminal Procedures

Terminal procedures are summarized in Terminal procedures anticoagulant) was obtained by jugular venipuncture from main animals only. Samples were

Text Table 9 **Terminal Procedures**

Ro. of Animals Group No. M F		Scheduled	Scheduled Necropsy Procedures			and embe		
		F	Euthanasia Day	Necropsy	Tissue O Gecropsy Collection Wo		Histology	Histopathology
1	10	10				Olice	Full Tissue ^a	Full Tissue ^a
2	10	10	44	X			Full Tissue ^a	Gross Lesions Target Tissues
3	10	10			MOPORISALIE	12/4	Full Tissue ^a	Gross Lesions Target Tissues
4	10	10		· ·	1110 10.		Full Tissue ^a	Full Tissue ^a
1	5	5		61	10.40	v	Full Tissue ^a	Full Tissue ^a
4	5	5	57	Xillo	,X	X	Full Tissue ^a	Full Tissue ^a
Unscheduled Deaths			NX N	X	-	Full Tissue ^a	Full Tissue ^a	

X = Procedure conducted; - = Not applicable.

4.13.1. Unscheduled Deaths

A complete necropsy was conducted for one control animal assigned to recovery study that died during dosing, and specified tissues were saved. Animal was refrigerated before necropsy to minimize autolysis.

4.13.2. Scheduled Euthanasia

Main study and recovery animals surviving until scheduled euthanasia had a terminal body weight recorded, samples for laboratory evaluation were collected (as appropriate), and were euthanized by exsanguination by incision from the abdominal agra following isoflurane anesthesia. The animals were euthanized rotating across dose groups such that similar numbers of animals from each group, including controls, were necropsied throughout the day. Animals were fasted overnight before their scheduled necropsy.

4.13.3. Necropsy

Main study and recovery animals were subjected to a complete necropsy examination, which included evaluation of the carcass and musculoskeletal system; all external surfaces and orifices;

See Tissue Collection and Preservation table for listing of tissues.

cranial cavity and external surfaces of the brain; and thoracic, abdominal, and pelvic cavities with their associated organs and tissues.

Necropsy procedures were performed by qualified personnel with appropriate training and experience in animal anatomy and gross pathology. A veterinary pathologist, or other suitably qualified person, was available.

4.13.4. Organ Weights

The organs identified in Text Table 10 were weighed at necropsy for all scheduled euthanasia animals. Organ weights were not recorded for animal found dead. Paired organs were weighed together. In the event of gross abnormalities, in addition to the combined weight, the weight of each organ of a pair may be taken and entered as a tissue comment. Organ to body weight ratio (using the terminal body weight) and organ to brain weight ratios were calculated.

Text Table 10 Organs Weighed at Necropsy

Brain	Liver
Epididymis ^a	Sung
Gland, adrenala	Ovarya
Gland, pituitary	Spleen
Gland, prostate	Testis ^a
Gland, thyroid ^a	Thymus
Heart	Uterus
Kidney ^a	5000

Paired organ weight.

4.13.5. Tissue Collection and Preservation

Just ide Juffered for Juffered for Juffered for Juffered for Juffered for Juffered Juffered Juffered Juffered Juffered for Representative samples of the tissues identified in Text Table 11 were collected from all animals and preserved in 10% neutral buffered formalin, unless otherwise indicated.

Text Table 11 Tissue Collection and Preservation

Injection site ^c	Large intestine, rectum
Animal identification	Larynx
Artery, aorta	Liver
Body cavity, nasal	Lung
Bone marrow smear	Lymph node, mandibular
Bone marrow	Lymph node, mesenteric
Bone, femur	Lymph node, mandioular Lymph node, mesenteric Lymph node, Inguinal ^e Lymph node, Popliteal ^e Small intesting dyndenum
Bone, sternum	Lymph node, Popliteal ^e
Brain ^d	Sman intestine, duodenum
Cervix	Small intestine, ileum
Epididymis	Small intestine, jejunum
Esophagus	Muscle, skeletal
Eye ^a	Nerve, optic
Gland, adrenal	Nerve, sciatic
Gland, harderian	Ovary
Gland, mammary	Pancreas
Gland, parathyroid	Skin
Gland, pituitary	Spinal cord
Gland, prostate	Spleen
Gland, salivary	Stomach
Gland, seminal vesicle	Testis ^b
Gland, thyroid	Thymus
Gross lesions/masses	Tongue
Gut-associated lymphoid tissue	Trachea
Heart	Spinal cord Spleen Stomach Testis ^b Thymus Tongue Trachea Urinary bladder Uterus Vagina
Kidney	Uterus
Large intestine, cecum	Vagina
Large intestine, colon	

- ^a Preserved in Davidson's fixative.
- b Preserved in Modified Davidson's fixative.
- ^c Thigh site used for the last injection.
- d Seven brain levels examined included olfactory bulb (Examine in Body cavity, nasal section level 4).
- ^e Lymph node draining the last administration site used (unilateral examination).

4.13.6. Histology

Tissues identified in Text Table 11 (except animal identification, bone marrow smears and larynx) were embedded in paraffin, sectioned, mounted on glass slides, and stained with hematoxylin and eosin.

4.13.7. Histopathology

Histopathological evaluation was performed by a board-certified veterinary pathologist.

4.13.8. Peer Review

(Appendix 20)

A pathology peer review was conducted by a Sponsor-designated pathologist; PhD from Experimental Pathology Laboratories, Inc., Research Triangle Park, NC 27709, USA.

The peer review statement was included as an appendix to the Final Report.

4.13.9. Bone Marrow Smear Analysis

Two bone marrow smears were prepared from each euthanized animal, air dried, stained with Wright's Giemsa stain, and not coverslipped. Bone marrow smears were not evaluated. calculated between each scheduled interval as well as between the beginning and end of each phase calculated against 41.

CONSTRUCTED VARIABLES

Body Weight Gains

Organ Weight relative to Body Weight

scheduled intervals

Organ Weight relative to Brain Weight calculated against the brain weight for scheduled

intervals

All results presented in the tables of the report are calculated using non-rounded values as per the raw data rounding procedure and may not be exactly reproduced from the individual data presented.

STATISTICAL ANALYSIS

Numerical data collected on scheduled occasions for the listed variables were analyzed as indicated according to sex and occasion. Descriptive statistics number, mean and standard deviation (or %CV or SE when deemed appropriate) were reported whenever possible. Values may also be expressed as a percentage of predose or control values when deemed appropriate. Inferential statistics were performed according to the matrix below when possible, but excluded semi-quantitative data, and any group with less than 3 observations.

Text Table 12 Statistical Matrix

	Statistical Method
Variables for Inferential Analysis	Parametric/ Non-Parametric
Body Weight	X
Hematology Variables	X
Coagulation Variables	X
Clinical Chemistry Variables	X
Cytokines	X
Body Temperature	X
α2-macroglobulin	X
α1-acid glycoprotein	X
Organ Weights	X
Body Weight Gains	X
Organ Weight relative to Body Weight	X
Organ Weight relative to Brain Weight	X

The following pairwise comparisons were made:

Group 2 Group 1

Group 3 Group 1

Group 4 Group 1 VS.

6.1. Parametric/Non-parametric

Levene's test was used to assess the homogeneity of group variances parametric assumption at the 5% significance level. Datasets with at least 3 groups were compared using an overall one-way ANOVA *F*-test if Levene's test was not significant or the Kruskal-Wallis test if it was. If the overall *F*-test or Kruskal-Wallis test was found to be significant, then the above pairwise comparisons were conducted using Dunnett's or Dunn's test, respectively.

Datasets with 2 groups (the designated control group and 1 other group) were compared using a *t*-test if Levene's test was not significant or Wilcoxon Rank-Sum test if it was.

All significant pairwise comparisons were reported at the 0.1, 1, and 5% significance levels.

7. COMPUTERIZED SYSTEMS

Critical computerized systems used in the study are listed below or presented in the appropriate Phase Report. All computerized systems used in the conduct of this study have been validated; when a particular system has not satisfied all requirements, appropriate administrative and procedural controls were implemented to assure the quality and integrity of data.

Text Table 13 Critical Computerized Systems

System Name	Version	Description of Data Collected and/or Analyzed		
Provantis	8 2	In-life; clinical pathology; postmortem		
Dispense	8 Shiok	Test Material receipt, accountability and/or formulation activities		
In-house reporting software Nevis (using SAS)	Nevis 2 (SAS 9.2)	Statistical analyses of numerical in-life, clinical pathology and postmortem data		
Mesa Laboratories AmegaView CMS	v3.0 Build 1208.8	Continuous Monitoring System. Monitoring of standalone fridges, freezers, incubators, and selecte laboratories to measure temperature, relative humidit and CO ₂ , as appropriate		
Johnson Controls Metasys	MVE 7.0 and 4.0	Building Automation System. Control of HVAC and other building systems, as well as temperature/humidity control and trending in selected laboratories and animal rooms		
Empower 3 (Waters Corporation)	Build 3471 SR1	Data acquisition for dose formulation analysis, including regression analysis and measurement of concentration and recovery of dose formulations using HPLC		
Bio Plex Manager (Bio-Rad)	6.1	Cytokine data collection		
Softmax Pro GxP	5.4.6	Cytokine data collection		
Watson LIMS	7.4.2 SP1	Sample tracking/analysis/regression - biomarkers		
Dynamics (Wyatt)	7.1.9.3	Data acquisition for particle size analysis for the test item using DLS		

RETENTION OF RECORDS, SAMPLES, AND SPECIMENS

All study-specific raw data, documentation, study plan, samples, specimens, and final reports Electronic data generated by the Test Facility were archived as noted above, except that the data collected using Provantis 8 and reporting files stored on SDMS, which were archived at the Charles River Laboratories facility location in Wilmington MAA

All records, retained samples and specimens, and reports generated from phases or segments performed by Test Facility-designated subcontractors were returned to the Test Facility for archiving Archival location and duration are detailed in the applicable PI report(s) or details regarding the retention of the materials were provided to the Study Director for inclusion in the Final Report.

as genre returne.
applicable PI
Study Director fo
Study Director fo
Study Director fo
And the life and the All records, retained samples and specimens, and reports generated from phases or segments performed by Sponsor-designated subcontractors were returned to the Test Facility for archiving Archival location and duration are detailed in the applicable PI report(s) or details regarding the retention of the materials were provided to the Study Director for inclusion in the Final Report.

RESULTS

9.1. Dose Formulation Analyses

Dose formulation concentration results were within specification. Homogeneity testing showed that the formulation technique used produced homogeneous preparations.

9.2. End of Use Ball To Sorvaliation

9.2. End of Use Bulk Test Item Analysis

(Appendix 3)

The bulk Test Item analysis demonstrated that the Test Item was suitable for use during the study period; the concentration, purity and particle size results obtained were consistent with the revised Summary of Analysis.

9.3. Mortality

(Appendix 4)

There were no mRNA-1647-related mortalities during the course of the study.

One male (No. 1014) given the Reference Item was found dead on Day 43. The pathological evaluation revealed a small, dark discoloration, and soft abnormal consistency of the right adrenal gland without histopathology correlates; a dark discoloration of the corticomedullary junction of the kidneys without histopathology correlates; a dark focus and dark discoloration of the thymus (incidental thymic hemorrhage); and a failure of the lungs to collapse (lung congestion). Histopathology findings for this control male were incidental and did not explain the cause of death for this animal.

9.4. Clinical Observations
(Table 1 and Appendix 5)
On the day following the last dosing occasion, a dose-related (in severity) soft swelling was noted on the last injection site (i.e. the right hindlimb). Firm swelling (severe) was also noted at the injection site of individual males and females given 89 µg/dose. The firm swelling was noted two days following the third dose and, for one male only, 1 day following the last dose. In addition, skin redness at the injection site, was noted at a higher incidence throughout the dosing period for animals given 89 µg/dose.

Given the absence of swelling or redness at the injection site 3 days following the last dose and 9.5. Local Irritation Assessment
(Appendix 5)
Slight throughout the recovery period, these clinical observations were considered fully reversed.

Slight to severe edema was noted at the injection site following dosing of males and females given $\geq 8.9 \,\mu\text{g/dose}$. The incidence and severity of these findings were dose-dependent. The apex of severity was noted 24 hours postdose and generally decreased 72 hours postdose.

Sporadic, slight to (rare) moderately severe erythema, noted at the injection site, was considered mRNA-1647-related only at 89 µg/dose and occurred generally following the third and fourth (last) doses.

Edema and erythema were no longer observed one week into the recovery period, and as such, they were considered completely reversed.

9.6. Body Weights and Body Weight Gains

(Figure 1, Figure 2, Table 2, Table 3, Appendix 6 and Appendix 7)

When compared to controls, following each dose, a tendency towards lower mean body weight gains was noted in males given $\geq 8.9 \,\mu\text{g/dose}$ and in females given $89 \,\mu\text{g/dose}$; these changes sometimes reached statistical significance. The changes were only cumulative in males and were down to 0.86X controls from Day -1 to 42. The body weight changes were generally comparable or rebounded during the 2-week recovery period.

9.7. Food Consumption

(Table 4 and Appendix 8)

Given the variability in weekly food consumption results, the occasional weekly changes, with no clear dose-relationship, were considered not mRNA-1647-related.

9.8. Opthalmology
(Appendix 15)
There were no mRNA-1647-related ocular changes observed during the course of the study. The findings noted were age-related or incidental in origin and to be expected in this population of animals.

9.9. Body Temperature

(Table 5 and Appendix 9)

In general body temperatures were within normal ranges of 36-38°C. When compared to control animals and pre-dose body temperature measurements, the mean body temperature appeared minimally increased in males and females given 89 µg/dose, 6 and/or 24 hours post Day 1 and Day 43 doses. These statistically-significant changes were considered mRNA-1647-This document cannot be

9.10. Hematology

(Table 6 and Appendix 10)

mRNA-1647-related hematology changes were noted for males and females starting at 8.9 µg/dose and included increases in neutrophil (NEUT), eosinophil (EOS) and/or large unstained cell (LUC) counts (with concomitant increases in white blood cell [WBC] counts) and decreases in lymphocyte (LYMPH) and platelet (PLT) counts. These changes are illustrated in SiOns of War Text Table 14.

Text Table 14 **Hematology Changes**

Dose (μg/dose)		8.9		27	SUS, 8	9
Parameter	Males	Females	Males	Females	Males	Females
WBC					10,00	
Day 44	-	1.2	1.3	1.4	1.8	1.8
Day 57				, ' ن	0 1.1	1.1
NEUT				31, 40,		
Day 44	1.8	4.6	4.4	6.2	7.2	8.9
Day 57				190 ° 20	0.63	0.95
LYMPH			.6	10 13		
Day 44	0.84	0.73	0.74	0.73	0.77	0.83
Day 57			67,00,00		1.2	1.2
EOS		-00	Jil JO			
Day 44	2.6	4.0	2.8	3.9	3.8	6.5
Day 57		07.0	,0°		1.0	1.2
LUC		Mo alli	0			
Day 44	2.2	0 19 7	2.2	2.1	1.8	2.0
Day 57		33,50,	-		1.1	0.81
PLT		The Co				
Day 44	- ~?) ;;(O) -	-	-	-	0.82
Day 57	4	(O)	-		_	1.1

Changes are expressed as X Fold from mean Group 1 (control) value.

Bolded values were statistically significant.

Shaded boxes indicate no collection at this timepoint for corresponding groups.

Mild to moderate increases in WBC counts (up to 1..8X controls for both genders) were noted in males given $\geq 27 \text{ ug/dose}$ and females given $\geq 8.9 \text{ µg/dose}$, mainly due to minimal to moderate increases in NEUT, LUC (up to 7.2X and 2.2X controls for males and 8.9X and 2.1X controls for females) and/or EOS (up to 3.8X controls for males and up to 6.5X controls for females). Minimal decreases in LYMPH counts were noted for males and females at $\geq 8.9 \,\mu\text{g/dose}$ (down to 0.74X and 0.73X controls, respectively).

Minimal decreases in PLT were noted in females given 89 µg/dose (0.82X controls).

Of the above changes noted following the dosing period, a full recovery of the findings were noted following the 2-week recovery period.

Any other differences in hematology parameters, including those attaining statistical significance, were judged to be due to individual or biological variation or lacked true dose relationship and therefore were considered not mRNA-1647-related.

^{-:} indicates results were considered not to be meaningfully different from mean control value.

9.11. Coagulation

(Table 7 and Appendix 11)

mRNA-1647-related increases in activated partial thromboplastin time (APTT) and in fibrinogen (FIB) were noted in males and females given $\geq 8.9 \ \mu g/dose$. The changes are illustrated in Text Table 15.

Text Table 15 Coagulation Changes

Dose (μg/dose)	8.9		27		89		
Parameter	Males	Females	Males	Females	Males	Females	
APTT							
Day 44	1.1	1.2	1.1	1.2	1,2	1.2	
Day 57					0.99	0.96	
FIB	Emiros virtos en				(0,00)		
Day 44	1.7	1.7	1.9	1.9	2.1	2.1	
Day 57					0.95	1.1	

Changes are expressed as X Fold from mean (Group 1) control value.

Bolded values were statistically significant.

Shaded boxes indicate no collection at this timepoint for corresponding groups.

Minimal increases in APTT were noted for males and females given $\geq 8.9 \,\mu\text{g}/\text{dose}$ (up to 1.2X controls for both genders). Mild increases in FIB were noted for males and females given $\geq 8.9 \,\mu\text{g}/\text{dose}$ (up to 2.1X controls for both genders). At the end of the 2-week recovery period, changes were fully recovered.

Any other differences in the coagulation parameters were judged to be due to individual or biological variability or lacked true dose relationship and therefore were considered not mRNA-1647-related.

9.12. Clinical Chemistry

(Table 8 and Appendix 12)

mRNA-1647-related decreases in albumin (ALB) and increases in globulin (GLOB) were noted for males and females; these changes were reflected by overall decrease in A/G ratio. The changes are illustrated in Text Table 16.

Text Table 16 Clinical Chemistry Changes

Dose (µg/dose) Parameter	8.9		27		89	
	Males	Females	Males	Females	Males	Females
ALB O	•					
Day 44	0.9	0.9	0.9	0.9	0.9	0.9
Day 57					1.0	0.9
GLOB	Particular Control of					•
Day 44	1.2	1.2	1.2	1.2	1.3	1.2
Day 57					0.9	1.0
A/G	100000000000000000000000000000000000000					
Day 44	0.8	0.8	0.8	0.8	0.7	0.7
Day 57					1.1	0.9

Changes are expressed as X Fold from mean Group 1 (control) value.

Bolded values were statistically significant.

Shaded boxes indicate no collection at this timepoint for corresponding groups.

Minimal decreases in ALB and minimal increases in GLOB were noted for males and females given $\geq 8.9 \,\mu\text{g/dose}$ (0.9X controls and up to 1.3X controls respectively) and affected the A/G ratio (down to 0.7X controls, for both genders). At the end of the 2-week recovery period, changes were fully recovered.

ansions of Variations thereof Any other differences in the clinical chemistry parameters, including those attaining statistical significance, were judged to be due to individual or biological variability or lacked true dose relationship and therefore were considered not mRNA-1647-related.

9.13. Alpha-1-Acid Glycoprotein

(Table 9, Appendix 13 and Appendix 18)

When compared to controls, statistically-significant dose-related increases in Alpha-1-Glycoprotein were noted in males and females, following the dosing period.

Following the 2-week recovery period, the concentrations of Alpha-1-Glycoprotein were comparable in both the controls and the males and females that were previously given 89 µg/dose, suggesting a full recovery.

9.14. Alpha-2-Macroglobulin

(Table 9, Appendix 13 and Appendix 18)

When compared to controls, dose-related increases in Alpha-2-Macroglobulin was noted in males and females, following the dosing period.

Following the 2-week recovery period, the concentrations of Alpha-2-Macroglobulin were still slightly higher than controls, suggesting only a partial recovery.

9.15. Cytokines

(Table 10, Appendix 14 and Appendix 18)

When compared to controls, statistically-significant higher concentrations of IP-10 were observed in both genders given 89 µg/dose at all timepoints, except on Day 57 (end of recovery) where the IP-10 concentrations were comparable to control levels. The highest IP-10 concentrations were generally observed 6 hours post Day 1 dose.

Higher concentrations of MCP-1 were noted in Test Item-given females on Days 1, 15 and 29, 6 hours postdose; the increases were statistically significant. MCP-1 concentrations were comparable to control levels on Day 57.

No mRNA-1647-related changes were observed in IL-1β, IL-6, MIP-1α and TNF-α levels.

9.16. Anti-Therapeutic Antibody (ATA)

(Appendix 16)

The Day 43 samples from mRNA-1647-treated Main Study animals had detectable antibody responses against CMV gB protein and CMV gH pentamer complex. The Day 57 samples from Recovery Study animals previously given 89 µg/dose had similar antibody titers compared to Day 43 titers.

9.17. PBMC

(Appendix 17)

T-cell responses were evaluated by assessment of Interferon gamma (INF γ) producing T cells. The results are detailed in the following tables.

				Dose level	Pentamer specific CD4+ T Cells			Pentamer specific CD8+ T Cells			
	Group	Test material	N	(μg)	Range (%)*;	Mean (%);	SD	Range (%)*;	Mean (%);	SD	
	1	Reference	9	0	0.00-0.46;	0.03;	0.30	0.00-0.32;	0.01;	0.23	
les	2	mRNA-1647	10	8.9	0.00-1.20;	0.04;	0.52	0.00-2.73;	0.43;	0.88	
Males	3	mRNA-1647	10	27	0.00-0.46;	0.08;	0.25	0.00-0.74;	0.21;	0.33	
	4	mRNA-1647	10	89	0.00-6.99;	0.90;	2.19	0.00-8.96;	1.29;	2.83	
	1	Reference	10	0	0.00-1.13;	0.02;	0.70	0.00-0.33;	0.01;	0.24	
ales	2	mRNA-1647	10	8.9	0.00-1.39;	0.09;	0.78	0.00-3.91;	1.10;	1.61	
Females	3	mRNA-1647	10	27	0.00-2.16;	0.34;	1.01	0.00-2.70;	0.69;	1.30	
	4	mRNA-1647	10	89	0.00-3.16;	0.31;	1.42	0.00-4.35;	0.95;	1.56	

Summary of Glycoprotein B Specific INF y Response

				Dose level		otein specific + T Cells			Glycoprotein specific CD8+ T Cells		
	Group	Test material	N	(μ g)	Range (%)*;	Mean (%);	SD	Range (%)*;	Mean (%);	SD	
	1	Reference	9	0	0.00-0.57;	0.00;	0.31	0.00-0.12;	0.00;	0.17	
les	2	mRNA-1647	10	8.9	0.00-0.79;	0.00;	0.38	0.00-0.26;	0.00;	0.13	
Males	3	mRNA-1647	10	27	0.00-0.91;	0.15;	0.35	0.00-0.64;	0.13;	0.28	
	4	mRNA-1647	10	89	0.00-3.17;	0.53;	0.99	0.00-4.52;	0.46;	1.46	
	1	Reference	10	0	0.00-0.79;	0.04;	0.41	0.00-0.69;	0.13;	0.36	
ales	2	mRNA-1647	10	8.9	0.00-1.30;	0.03;	0.92	0.00-0.00;	0.00;	0.37	
Females	3	mRNA-1647	10	₹27	0.00-2.15;	0.08;	1.28	0.00-4.17;	0.71;	1.62	
	4	mRNA-1647	210	89	0.00-3.00;	0.00;	1.62	0.00-4.76;	0.79;	1.96	

^{*} For purpose of Range and Mean calculation, value <0.00 following unstimulated Control subtration were set to 0.00 for reporting

Maximal antigen-specific response was observed at 89 μ g/dose for both Pentamer and Glycoprotein B peptide libraries. The Pentamer library produced the stronger response of the two antigen libraries with an individual maximal response in males of up to 6.99 and 8.96% in CD4+ and CD8+ T cells, respectively. The largest response to Glycoprotein B stimulation was at 89 μ g/dose in males for CD4+ T cells at 3.17%, and in females at 4.76% for CD8+ T cells.

9.18. Gross Pathology

(Appendix 19)

9.18.1. Terminal Necropsy (Day 44)

mRNA-1647-related gross pathology findings are summarized in Text Table 17.

Text Table 17
Summary of Gross Pathology Findings – Terminal Necropsy (Day 44)

		M	lales		Females				
Group	1	2	3	4	1	2	3	4	
Dose (μg/dose)	0	8.9	2 7	89	0	8.9	27	89	
No. Animals Examined	10	10	10	10	10	10	10	10	
Site, Injection (No. Examined)	10	10	10	10	10	10	10	10	
Abnormal consistency, firm	0	1	5	9	0	3	5	10.7	
Swelling	0	5	6	9	0	5	5	7	
Focus, dark	0	0	0	0	0	1	1,0	3	
Lymph Node, Inguinal (No. Examined)	10	10	10	10	10	10	S 10	10	
Enlargement	1	1	0	5	0	0 0	0,	1	
Lymph Node, Popliteal (No. Examined)	10	10	10	10	10	100	210	10	
Enlargement	0	3	7	7	0	7 8 8 OC)	6	7	

At the intramuscular injection sites, dose-dependent mRNA-1647-related gross pathology observations of abnormal firm consistency, dark focus, and/or swelling were noted in animals given $\geq 8.9~\mu g/dose$. These gross observations correlated microscopically with mixed cell inflammation of the subcutaneous and/or muscular tissue and/or subcutaneous edema at the injection site.

In the draining inguinal and/or popliteal lymph nodes, mRNA-1647-related gross enlargement was noted in animals given $\geq 8.9~\mu g/dose$, and correlated microscopically to mixed cell inflammation. Gross enlargement and microscopic mixed cell inflammation most commonly involved the popliteal lymph nodes. Gross enlargement of the inguinal lymph node was noted in one male given the Reference Item, without any correlating microscopic finding.

Other gross pathology findings observed were considered incidental, of the nature commonly observed in this strain and age of rats, and/or were of similar incidence in Reference and Test Item-treated animals and, therefore, were considered not mRNA-1647-related.

9.18.2. Recovery Necropsy (Day 57)

(Appendix 19)

There were no mRNA-1647-related gross pathology findings observed at the end of the 2-week recovery period.

All gross pathology findings observed were considered incidental, of the nature commonly observed in this strain and age of rats, and/or were of similar incidence in Reference and Test Item-treated animals and, therefore, were considered not mRNA-1647-related.

9.19. Organ Weights

(Appendix 19)

9.19.1. Terminal Necropsy (Day 44)

(Appendix 19)

mRNA-1647-related organ weight changes are summarized in Text Table 18.

Text Table 18
Summary of Organ Weight Data – Terminal Necropsy (Day 44)

		Males		Females			
Group	2	3	4	2		4	
Dose (μg/dose)	8.9	27	89	8.9	+27	89	
No. Animals per Group	10	10	10	10	7 10	10	
Spleen (No. Weighed)	10	10	10	10	10	10	
Absolute weight	1.0794	1.0824	1.2070 b	0.7125	0.7566 a	0.7934 ^b	
% of body weight	0.21190 a	0.21678 a	0.23429 °	0.22732	0.24041 b	0.25394 °	
% of brain weight	48.79592	49.81185	55.10209 ^в	34.70430	36.98272 a	38.80259 b	

- ^a Significantly different from Group 1 value p≤0.05 (Dunnett).
- ^b Significantly different from Group 1 value p≤0.01 (Dunnett).
- Significantly different from Group 1 value p≤0.001 (Dunnett).

 Based upon statistical analysis of group means, values highlighted in bold are significantly different from control group P ≤ 0.05; refer to data tables for actual significance levels and tests used.

In the spleen, slight dose-dependent increases in absolute and/or relative organ weights were noted in males and females given $\geq 8.9~\mu g/dose$. These changes were consistently statistically significant for increases in absolute and/or relative (to body and/or to brain) weights in males given $89~\mu g/dose$ and females given $\geq 27~\mu g/dose$. These splenic weight changes were not correlated with any specific histopathology finding.

No other mRNA-1647-related organ weight changes were noted. There were other isolated organ weight values that were statistically different from their respective controls. There were, however, no patterns, trends, or correlating data to suggest these values were toxicologically relevant. Thus, other organ weight differences observed were considered incidental and/or related to difference of sexual maturity and not mRNA-1647-related.

9.19.2. Recovery Necropsy (Day 57)

(Appendix 19)

mRNA-1647-related increased spleen weights noted at the terminal necropsy were also observed at the end of the 2-week recovery period and are summarized in Text Table 19.

		Males			Females			
Group	2	3	4	2	3	4		
Dose (μg/dose)	8.9	27	89	8.9	27	89		
No. Animals per Group	0	0	5	0	0	5		
Spleen (No. Weighed)	0	0	5	0	0	5 ::(
Absolute value	-	_	1.1022	-	-	0.6522		
% Difference	-	_	+18.90	-	-	+9.65		
% of body weight	-	_	0.18856 a	-	-	0.20057		
% Difference	-	_	+21.50	-	-	+11.74		
% of brain weight	_	_	48.35552	-	00	31.90101		
% Difference			+10.86		CIC	±11 50		

Text Table 19
Summary of Organ Weight Data – Recovery Necropsy (Day 57)

Based upon statistical analysis of group means, values highlighted in bold are significantly different from Group $1-P \le 0.05$; refer to data tables for actual significance levels and tests used.

In the spleen, a slight increase in absolute and/or relative organ weights were noted in males and females given 89 μ g/dose. These changes were not statistically significant, with the exception of mean spleen weight relative to final body weight in the males; and thus, were considered to have limited toxicological importance. These splenic weight changes were not correlated with any specific histopathology finding.

No other mRNA-1647-related organ weight changes were noted. There were other isolated organ weight values that were statistically different from their respective controls. There were, however, no patterns, trends, or correlating data to suggest these values were toxicologically relevant. Thus, other organ weight differences observed were considered incidental and/or related to difference of sexual maturity and not mRNA-1647-related.

9.20. Histopathology

(Appendix 19)

9.20.1. Terminal Necropsy (Day 44)

(Appendix 19)

mRNA-1647-related microscopic pathology findings were noted at the injection sites, the draining lymph nodes (popliteal and/or inguinal), sciatic nerve, bone marrow, and spleen and these findings are summarized in Text Table 20

^a Significantly different from Group 1 value p≤0.05 (T-Test).

Text Table 20
Summary of Microscopic Findings – Terminal Necropsy (Day 44)

		M	ales			Fem	a Los	
C	1	2		4	1	2 rem		4
Group	1		3	-	1	_	3	
Dose (μg/dose)	0	8.9	27	89	0	8.9	27	89
No. Animals Examined	10	10	10	10	10	10	10	10
Site, Injection (No. Examined)	10	10	10	10	10	10	10	10
Inflammation: mixed cell; subcutaneous	0	10	9	10	0	10	10	10
Minimal	-	1	0	0	0	1	1	N. P.
Mild	-	6	3	4	0	7	8	3° 2
Moderate	-	3	6	6	0	2	10	7
Edema; subcutaneous	0	5	8	9	0	6	8	10
Minimal	-	2	0	2	-	2	0.5	0
Mild	-	3	2	3	-	3	4	3
Moderate	-	0	6	4	-	4	2	7
Degeneration; myofiber	5	7	9	6	5 \	500	8	6
Minimal	5	7	8	5	4	4.	6	6
Mild	0	0	1	1	<i>à 6</i>	(P) 1	2	0
Lymph Node, Popliteal (No. Examined)	10	10	10	10	0100	10	10	10
Inflammation; mixed cell	0	2	10	9 8		10	10	10
Minimal	_	0	2	A.	5	4	2	0
Mild	_	2		(C3 / C	_	6	7	5
Moderate	_	0	4.0	9,01	_	0	1	5
Marked	_	0 0	4 4 0	\ 1	_	0	0	0
Lymph Node, Inguinal (No. Examined)	10	10		10	10	10	10	10
Inflammation; mixed cell	0	200.6	300	3	0	0	0	0
Minimal	-0	11 2/13	0/1	1	_	_	_	_
Mild	<i>₽</i> .	11/2 V	0	2	_	_	_	_
Sciatic Nerve (No. Examined)	10	100	10	10	10	10	10	10
To Manage at a manage at a second and the second	(A)	10	10	10	0	10	10	10
Minimal	/////s	0	2	1	_	4	3	1
Mild		2	4	1	_	2	4	1
Moderate	(O)	3	4	8	_	4	3	7
Minimal Mild Moderate Marked Bone Marrow (No. Examined) Increased homotopoiosis; mysloid	_	5	Ö	ő	_	ò	0	1
Bone Marrow (No. Examined)	10	10	10	10	10	10	10	10
Increased hematopoiesis; myeloid	0	0	4	9	0	0	2	9
Minimal Minimal	-	-	4	9	_	-	2	9
Spleen (No. Examined)	10	10	10	10	10	10	10	10
	10	10	10		10	10		
Decreased cellularity; periarteriolar	0	5	9	10	0	7	10	10
lymphoid sheath		1	5	2		_	6	1
Minimal No.	-	1	5 4	3 7	-	5 2	6 4	1 9
Mild &	-	4	4	1	-		4	9

Localized tissue reactions involved the intramuscular injection sites, the draining popliteal and/or inguinal lymph nodes, and the sciatic nerves. Systemic tissue reactions involved the bone marrow and spleen.

At the intramuscular injection sites, there was a dose-related inflammatory reaction characterized by minimal to moderate mixed cell inflammation involving the subcutaneous tissues, skeletal muscle, and to a lesser extent the dermis, as well as associated minimal to moderate subcutaneous edema and minimal to mild myofiber degeneration in animals given $\geq 8.9 \,\mu\text{g/dose}$. The inflammatory reaction, which increased in severity with increasing dose, often extended along and expanded endomysial and perimysial tissue layers, encircling individual muscle fibers

and/or bundles. This reaction was characterized by varying numbers of intact and degenerating neutrophils, mononuclear cells, and macrophages (mixed cell inflammation); accumulations of protein-rich fluid (edema); and varying degrees of myofiber degeneration.

In the draining popliteal and/or inguinal lymph nodes, an increased incidence and/or severity of minimal to marked mixed cell inflammation were noted in animals given $\geq 8.9 \,\mu\text{g}/\text{dose}$. The inflammation often involved the adventitia surrounding the lymph nodes, and most commonly involved the popliteal lymph nodes.

Minimal to marked mixed cell inflammation was frequently observed in the perineurial tissue surrounding the sciatic nerve of animals given $\geq 8.9 \,\mu\text{g/dose}$. This finding was considered to be an extension of the inflammatory reaction at the intramuscular injection sites to this region.

In the bone marrow, minimal increased myeloid hematopoiesis was noted in animals given \geq 27 µg/dose. This finding was characterized by increased numbers of myeloid precursors in the marrow, and was secondary or compensatory inflammatory reaction noted at the intramuscular injection sites.

In the spleen, a dose-dependent minimal to mild decreased cellularity of the periarteriolar lymphoid sheath was noted in animals given $\geq 8.9 \,\mu\text{g/dose}$.

Other microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of rats, and/or were of similar incidence and severity in Reference and Test Item-treated animals and, therefore, were considered not mRNA-1647-related.

9.20.2. Recovery Necropsy (Day 57)

(Appendix 19)

Following the 2-week recovery period, microscopic pathology findings seen at the terminal necropsy were no longer present in the draining lymph nodes (popliteal and/or inguinal), consistent with a complete recovery of these findings.

Microscopic findings noted at the terminal necropsy were also observed at the recovery necropsy at the injection sites (however, a shift to mononuclear cell infiltration rather than mixed cell inflammation was observed), sciatic nerve, bone marrow, and spleen and these findings are summarized in Text Table 21.

Text Table 21
Summary of Microscopic Findings – Recovery Necropsy (Day 57)

	N	Iales	Fe	emales
Group	1	4	1	4
Dose (μg/dose)	0	89	0	89
No. Animals Examined	4	5	4	5
Site, Injection (No. Examined)	4	5	5	5
Infiltration, mononuclear cell; myofiber	0	2	0	5 ili ⁰
Minimal	-	1	-	4
Mild	-	1	-	11,0
Nerve, Sciatic	4	5	5	05
Inflammation, mixed cell; perineurial	0	0	0	× 2
Minimal	-	-	- ;	2
Bone Marrow (No. Examined)	4	5	5	5
Increased hematopoiesis; myeloid	0	2	0+	1
Minimal	-	2	7-0,00	1
Spleen (No. Examined)	4	5	50	5
Decreased cellularity; periarteriolar lymphoid	0	2)	0
sheath	U	2	* OLIV	U
Minimal	-	200	R -	-

At the intramuscular injection sites, there was a residual inflammatory reaction characterized by minimal to mild mononuclear cell infiltration involving the subcutaneous tissues and skeletal muscle at $89 \mu g/dose$. Minimal to mild myofiber degeneration did not differ in incidence or severity from the Reference Item-treated group

Mixed cell inflammation involving the draining lymph nodes (popliteal and/or inguinal) and sciatic nerves, as noted as the terminal euthanasia, was not noted at the recovery necropsy, consistent with complete recovery.

Minimal mixed cell inflammation was observed in the perineurial tissue surrounding the sciatic nerve of females given 89 μ g/dose. The incidence and severity of this finding was reduced compared to the terminal necropsy.

In the bone marrow, minimal increased myeloid hematopoiesis was noted in animals given 89 µg/dose. The incidence of this finding was reduced compared to the terminal necropsy.

In the spleen, a minimal decreased cellularity of the periarteriolar lymphoid sheath was noted in males given 89 µg/dose. The incidence and severity of this finding was reduced compared to the terminal necropsy.

Other microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of rats, and/or were of similar incidence and severity in Reference and Test Item-treated animals and, therefore, were considered not mRNA-1647-related.

10. CONCLUSION

In conclusion, administration of mRNA-1647 by intramuscular injection for 6 weeks (4 doses) parameters) in rats up to 89 μg/dose. Starting at 8.9 μg/dose, generally dose-dependent changes in clinical signs at the injection site, clinical pathology parameters, cytokines and acute protein levels were consistent with an inflammatory response at the injection site. Dose-related to organ effects were limited to the injection site, the bone many lymph nodes, the connection. spleen of were partially, were partially, and the property of the partial partial and the partial part mRNA-1647. At the end of the 2-week recovery period, all changes were partially or fully

Figure 1




Figure 2




Table 1

				<u> </u>
	Day numbers relative	e to Start Date	5/5/8	-
			te.	
	0	8.9	27, 0,00	89
	ug/dose	ug/dose	ug/dose	ug/dose
Swollen Soft			id allo	
Number of Observat	ions .	10		13
Number of Animals	•	10	10	12
Days from - to	•	44 44	28 44	31 45
Swollen Firm		Jilos V.	5	
Number of Observat	ions .	20 40	•	4
Number of Animals	•	7) SK O.	•	3
Days from - to	2	100 101	•	31 44
Skin, Red	, o?.	E311 1/20		
Number of Observat	ions 2	7	1	7
Number of Animals	2 2	2	1	6
Days from - to	70 44	14 44	14 14	31 45
Skin, Lesion w/ Discharge	0.000			
Number of Observat	ions	1		
Number of Animals	To Ch	1	•	•
Days from - to	ions	-1 -1	•	
Skin, Scab	All ilati			
Number of Observat	ions 3	11	1	4
Number of Animals	3	4	1	2
Days from - to	7 44	-1 44	14 14	28 35
Fur, Erected	76			
Number of Observat	ions .	2	2	1
Number of Animals		2	2	1
Days from to	•	44 44	44 44	44 44
Fur, Staining Red				
Number of Observat	ions .	5		9
Number of Animals	•	2	•	3
Days from - to	•	28 44		14 57
COL				

Table 1

		Day numbers relativ	ve to Start Date	ans)	<u>)</u>
Sex: Male		0 ug/dose	8.9 ug/dose	27 ug/dose	89 ug/dose
	Fur, Thin Cover Number of Observations Number of Animals Days from - to	3 1 28 42	1 1 44 44	In September	1 1 44 44
	Malocclusion Number of Observations Number of Animals Days from - to	:	in solver	7 1 7 44	:
	Testis, Enlarged Number of Observations Number of Animals Days from - to	Sing Ship	1 1 28 28	:	:
	Digit Bent Number of Observations Number of Animals Days from - to	28 42 28 42	:	1 1 44 44	:

Table 1

Day num	bers relati	ve to Start Date	ells.	
Hyperreactive Number of Observations Number of Animals Days from - to Hypersensitive Number of Observations Number of Animals Days from - to Vocalization Increased Number of Observations Number of Animals Days from - to Caught in Cage Number of Observations Number of Animals Days from - to Swollen Soft Number of Observations Number of Animals Days from - to Swollen Firm Number of Observations Number of Animals Days from - to	0 ug/dose	8.9 ug/dose	27 ug/dose	89 ug/dose
Hyperreactive			10 NO	
Number of Observations	-	3	D' *81.	•
Number of Animals	•	1	7 00	•
Days from - to	•	35 44	50.	•
Hypersensitive		JICO V	3	
Number of Observations		260	•	8
Number of Animals		11 84 0,		1
Days from - to	. 0	1.0° 10''	•	7 44
Vocalization Increased	,09°	Call 1/20		
Number of Observations	م الله	(13 /02),	·	8
Number of Animals	8,700	, VO.		1
Days from - to	Ma Shi	0	•	7 44
Caught in Cage	0.00	-		
Number of Observations	SIII SO,	•	1	•
Number of Animals	0 (0		1	•
Days from - to	.101	•	28 28	•
Swollen Soft	gi.			
Number of Observations		10	11	14
Number of Animals	•	10	10	13
Days from - to	•	44 44	7 44	31 45
Swollen Firm				
Number of Observations		•	•	10
Number of Animals	•	•	•	10
Days from 5 to	•	•	•	31 31
Warm to Touch				
Number of Observations	•		•	2
Number of Animals	•	•	•	2
Days from - to	•	•	•	44 44
r Co				

Table 1

5002034

Day numbers relative to Start Date Sex: Female 0 8.9 89 ug/dose ug/dose ug/dose ug/dose Skin, Red 35 Number of Observations 2 15 Number of Animals 17 56 Days from - to Skin, Dry Number of Observations Number of Animals 21 57 Days from - to Skin, Lesion Number of Observations Number of Animals Days from - to Skin, Lesion w/ Discharge Number of Observations Number of Animals 1 Days from - to 28 28 Skin, Scab Number of Observations (14 Number of Animals Days from - to 28 57 Fur, Staining, Red Number of Observations 11 Number of Animals Days from to 35 57 14 44 21 44 21 57 Fur, Thin Cover Number of Observations Number of Animals Days from - to 28 57 57 57 -14 44

Table 1		Summary of Clinic			89	
		Day numbers relati	ve to Start Date		(<u>)</u>	
Sex: Female		0 ug/dose	8.9 ug/dose	27 ug/dose	89 ug/dose	
	Teeth, Broken Number of Observations Number of Animals Days from - to	: : :	, i	or September	8 1 -1 44	
	Skin Staining Number of Observations Number of Animals Days from - to	oma europa	isation applice	1 1 44 44	:	
		anymanketing EC				
	Teeth, Broken Number of Observations Number of Animals Days from - to Skin Staining Number of Observations Number of Animals Days from - to					

Table 2
Summary of Body Weights (g)

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose

Group	/				Day		4.20)
Sex		-12	-1	7	14	21	280	35
1M	Mean	159.5	269.5	336.4	404.4	457.7	500.5	536.7
IVI	SD	5.0	13.5	19.3	27.8	31.4	36.3	40.5
	N	15	15	15	15	145 OL 73	15	15
2M	Mean	158.3	266.7	323.6	384.4	429.3a	467.9	497.0a
	SD	5.2	12.1	17.6	23.3	30.0	42.9	48.7
	N	10	10	10	20 0	10	10	10
	%Diff G1	-0.7	-1.0	-3.8	-4.9 O	-6.2	-6.5	-7.4
M	Mean	158.3	259.3	312.0b	374.1b	417.6b	454.3b	484.9b
	SD	6.1	7.6	10.7	Ø 45.1	20.2	25.3	28.9
	N	10	10	10	10	10	10	10
	%Diff G1	-0.7	-3.8	-7.3 M	-7.5	-8.8	-9.2	-9.7
łМ	Mean	159.5	271.2	321.2a	391.5	428.1a	475.3	502.3a
	SD	4.8	14.9	16.2 15	20.1	22.6	26.0	27.2
	N	15	15	15	15	15	15	15
	%Diff G1	0.0	0.6.0	-4.5	-3.2	-6.5	-5.0	-6.4

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

Table 2 Summary of Body Weights (g)

Tabl	e 2			
Sum	mary of Bo	dy Weights	(g)	
_	1 - Reference	e Item 647 27 μg/dos	se	
Group			Day	
Sex	,	42	49	56 612.8 45.5 4 594.6 25.9 -3.0
13.6	Mean	567.5	596.3	612.9
1M	SD	46.3	44.3	45.5
	N	15	4	4
2M	Mean	521.8a		
	SD	52.1		
	N	10		
	%Diff G1	-8.0		
3M	Mean	514.1b		
	SD	34.1		
	N	10		<
	%Diff G1	-9.4		4
4M	Mean	538.7	563.0	594.6
	SD	29.2	27.1	25.9
	N	15	5	50,005
	%Diff G1	-5.1	-5.6	-3.0

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

Table 2 Summary of Body Weights (g)

								Test Facility
Table	e 2							Jaijail
Sumi	nary of Bo	dy Weights	s (g)					SOF
Group	1 - Reference	Item			_	2 - mRNA-1647	OIS MB GOOD	SIOT
Group	3 - mRNA-10	647 27 μg/do:	se		Group	4 - mRNA-1647	89 μg/dose	2
Group /	1	-13	-1	7	Day 14	21	and any 2881 2	35
1F	Mean	153.9	225.9	249.1	270.4	287.0	303.3	316.5
	SD	7.0	15.5	17.2	22.3	22.5	26.9	29.3
	N	15	15	15	15	95	15	15
2F	Mean	152.4	223.9	246.5	273.3	287.4	304.4	315.0
	SD	5.1	13.6	19.6	27.0	31.3	33.5	35.2
	N	10	10	10	010	10	10	10
	%Diff G1	-1.0	-0.9	-1.1	273.3 2730 10 131	287.4 31.3 10 0.1	0.4	-0.5
3F	Mean	151.2	220.2	244 =	270.4	286.6	305.3	316.9
	SD	6.0	12.2	18.0	26.6	25.6	31.2	33.1
	N	10	10	10	10	10	10	10
	%Diff G1	-1.8	-2.5	18.0 10 -1.8	0.0	-0.1	0.7	0.1
4F	Mean	153.1	225.1	242.7	270.6	282.3	299.5	309.4
	SD	6.5	9.2	13.6 15	18.7	20.9	20.4	26.1
	N	15	15)Y (015	15	15	15	15
	%Diff G1	-0.6	-0.4	-2.6	0.1	-1.6	-1.3	-2.2

Table 2 **Summary of Body Weights (g)**

	mary of Bo	dy Weights	5 (g)	
-	1 - Reference 3 - mRNA-1	e Item 647 27 μg/do	se	
Group Sex		42	Day 49	339.8 31.3 5 337.6 33.5 5 -0.6
1F	Mean	328.5	332.2	339.8
	SD	31.4	31.9	31.3
	N	15	5	5
2F	Mean	320.6		
	SD	36.5		
	N	10		
	%Diff G1	-2.4		
3F	Mean	327.0		
J1	SD	32.7		
	N	10		2
	%Diff G1	-0.5		Mar Kno
4F	Mean	323.1	328.8	337.6
	SD	26.1	36.6	33.5
	N	15	5 👊	5
	%Diff G1	-1.7	-1.0	-0.6

Table 3 Summary of Body Weight Gains (g)

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose

-121	Change C	n	/				Day		W. Kr.	
-121 -1 -7 7 -14 14 -21 21 -28 28 -35 3 IM Mean 110.0 66.9 68.0 53.3 42.9 36.2 3 SD 11.9 6.7 10.1 7.1 7.5 6.0 N 15 15 15 15 15 15 15 15 2M Mean 108.4 56.9b 60.8 44.9b 38.6 29.1a 2 SD 9.4 8.4 9.5 7.9 13.6 7.0 N 10 10 10 10 10 10 10 10 10 10 3M Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 2 SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 10 10 10 11 AM Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)	Mean 110.0 66.9 68.0 53.3 42.9 36.2 30.7 SD 11.9 6.7 10.1 7.1 7.5 6.0 6.7 N 15 15 15 15 15 15 15 15 15 15 15 15 15	sex		_	Change	Change	Change	Change	Change	Change
1M Mean 110.0 66.9 68.0 53.3 42.9 36.2 3 SD 11.9 6.7 10.1 7.1 7.5 6.0 N 15 15 15 15 15 15 2M Mean 108.4 56.9b 60.8 44.9b 38.6 29.1a 2 SD 9.4 8.4 9.5 7.9 13.6 7.0 7.0 N 10 10 10 10 10 10 10 10 10 3M Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 2 SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 1 4M Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15	M Mean 110.0 66.9 68.0 53.3 42.9 36.2 30.7 SD 11.9 6.7 10.1 7.1 7.5 6.0 6.7 N 15 15 15 15 15 15 15 15 15 15 15 15 15			-121	-1 - 7	7 - 14	14 - 21	21 - 28	28-35	35 - 42
SD 11.9 6.7 10.1 7.1 7.5 6.0 N 15 15 15 15 15 15 15 15 15 15 15 15 15	SD 11.9 6.7 10.1 7.1 7.5 6.0 6.0 6.7 N 15 15 15 15 15 15 15 15 15 15 15 15 15	1M	Mean	110.0	66.9	68.0	53.3	42.9	36.2	30.7
N 15 15 15 15 15 15 15 15 15 15 15 15 15	N 15 15 15 15 15 15 15 15 15 15 15 15 15		SD	11.9	6.7	10.1	7.1	7.50	6.0	6.7
2M Mean 108.4 56.9b 60.8 44.9b 38.6 29.1a 2 SD 9.4 8.4 9.5 7.9 13.6 7.0 N 10 10 10 10 10 10 10 10 3M Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 2 SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 10 10 4M Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 15 15 15 15	Mean 108.4 56.9b 60.8 44.9b 38.6 29.1a 24.8 SD 9.4 8.4 9.5 7.9 13.6 7.0 8.0 N 10 10 10 10 10 10 10 10 10 10 10 10 10		N	15	15	15	15	15	15	15
SD 9.4 8.4 9.5 7.9 13.6 7.0 N 10 10 10 10 10 1 3M Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 2 SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 10 4M Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 15 Significantly different from control group 1 value: a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)	SD 9.4 8.4 9.5 7.9 13.6 7.0 8.0 N 10 10 10 10 10 10 10 10 10 10 10 10 10	2M	Mean	108.4	56.9b	60.8	44.9b	38.6	29.1a	24.8
N 10 10 10 10 10 10 10 10 10 10 10 10 10	N 10 10 10 10 10 10 10 10 10 10 10 10 10		SD	9.4	8.4	9.5	7.9	13.6	7.0	8.0
3M Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 2 SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 10 10 10 4M Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 15 15 15 Significantly different from control group 1 value a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)	Mean 101.0 52.7c 62.1 43.5b 36.7 30.6 29.2 SD 7.4 8.2 5.6 6.7 7.6 4.8 7.4 N 10 10 10 10 10 10 10 10 10 10 10 10 10		N	10	10	10	6/10 OT 0	10	10	10
SD 7.4 8.2 5.6 6.7 7.6 4.8 N 10 10 10 10 10 10 10 10 10 10 10 10 10	SD 7.4 8.2 5.6 6.7 7.6 4.8 7.4 N 10 10 10 10 10 10 10 10 10 10 10 10 10	3M	Mean	101.0	52.7c	62.1	43.5b	36.7	30.6	29.2
N 10 10 10 10 10 10 10 10 10 14 10 10 10 10 10 10 10 10 10 10 10 10 10	N 10 10 10 10 10 10 10 10 10 10 10 10 10		SD	7.4	8.2	5.6	(6.7)	7.6	4.8	7.4
4M Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 3 SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 15 15 15 15 Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)	Mean 111.7 50.0c 70.3 36.6c 47.2 26.9c 36.4 SD 12.7 6.8 7.3 5.0 6.8 5.4 5.9 N 15 15 15 15 15 15 15 15 15 15 15 15 15		N	10	10	10	10	10	10	10
SD 12.7 6.8 7.3 5.0 6.8 5.4 N 15 15 15 15 15 15 15 15 15 15 15 15 15	SD 12.7 6.8 7.3 5.0 6.8 5.4 5.9 N 15 15 15 15 15 15 15 15 15 15 15 15 15	4M	Mean	111.7	50.0c	70.3	36.6c	47.2	26.9c	36.4
N 15 15 15 15 15 15 15 15 15 15 15 15 15	N 15 15 15 15 15 15 15 15 15 15 15 15 15	1141	SD	12.7	6.8	7.3	5.0	6.8	5.4	5.9
Significantly different from control group 1 value a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)	Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)			15	15	1500	15	15	15	15
	, camot by the				(0,01				
5002034 CHRENT		Signif	ficantly diffe	erent from control	group 1 value :a	=p≤0.05,b=p≤0.0	1,c=p≤0.001 (Du	nnett)		

Table 3 Summary of Body Weight Gains (g)

Group 3 - mRNA-1647 27 µg/dose

	/		D	ay	
Sex		Change	Change	Change	Change
		-1 - 42	42 - 49	49 - 56	42 - 56
1M	Mean	298.0	28.8	16.5	45.3
	SD	36.1	6.7		
	N	15	4	4	4
2M	Mean	255.1a		4.0 4 31.6e 7.6 5 	0.e ₀
	SD	47.3			.08° c2
	N	10			elikolis
3M	Mean	254.8a			US. 871170
	SD	34.9			(19 cm)
	N	10		- 12	ili Ki
4M	Mean	267.5	20.8	31.6e	52.4
	SD	23.9	3.6	7.6	7.0
	N	15	5	5,000	5
	ncantiv aim			=からいいつ か=からいい	
Signi		267.5 23.9 15 erent from control	group 1 value :a= d=p≤0.05	,e=p≤0.01,f=p≤0	.001 (T-test)

Table 3 Summary of Body Weight Gains (g)

Group 3 - mRNA-1647 27 μg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose

Group	1				Day		4.20	
Sex		Change	Change	Change	Change	Change	Change	Change
		-131	-1 - 7	7 - 14	14 - 21	21 - 28	28 - 35	35 - 42
4.5	M	72.0	22.2	21.2	16.6	16.2 : 0	13.2	10.1
1F	Mean	72.0	23.2	21.3	16.6	16.3		12.1
	SD	14.6	6.8	8.9	7.6	7.60	6.5	6.1
	N	15	15	15	15	ada, or	15	15
2F	Mean	71.5	22.6	26.8	14.1	2.0	10.6	5.6b
	SD	11.9	8.8	8.9	7.9	8.7	5.9	5.3
	N	10	10	10	@10 of o	× 10	10	10
3F	Mean	69.0	24.5	25.7	16.2	18.7	11.6	10.1
_	SD	13.9	9.1	11.3	10.4	9.0	5.9	3.9
	N	10	10	10	10	10	10	10
4F	Mean	72.0	17.6	27.9	11.7	17.2	9.9	13.7
	SD	9.5	6.9	7.7	7.9	4.1	7.8	4.0
	N	15	15	1500	15	15	15	15

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

5002034

Table 3 Summary of Body Weight Gains (g)

						Test Facility Study N
Γable	e 3					Valiation
Sumi	nary of B	ody Weight G	ains (g)			as of
-	1 - Reference 3 - mRNA-	ce Item 1647 27 µg/dose			Group 2 Group 4	2 - mRNA-1647 8.9 μg/dose 4 - mRNA-1647 89 μg/dose
Group / Sex	/	Change	Change 42 - 49	Day Change 49 - 56	Change 42 - 56	Test Facility Study N 2 - mRNA-1647 8.9 μg/dose 4 - mRNA-1647 89 μg/dose -
1F	Mean	102.6	7.2	7.6	14.8	"OL 66/6"
	SD	20.0	9.7	7.5	12.8	::CAN A
	N	15	5	5	5	applion of
2F	Mean	96.7			n	01.00
	SD	25.8			, 0 00,000	
	N	10			Sen HOLYO	X ²
3F	Mean	106.8		65	10 371,70	
	SD	25.4			10 cm	
	N	10		₍₁)	ii. (Fr	
4F	Mean	98.0	10.6	8.8	19.4	
	SD	19.1	6.7	10.0	6.3	
	N	15	5	5,000	5	

Table 4 Summary of Food Consumption (g/animal/day)

Tabl		od Congrum	ation (alonim	ol/dow)				Test Facility	Page Study No. 50020
	•	_	ption (g/anim	ai/day)		D.V. 1645	0.0 /1 **	ons	
-	1 - Reference	Item 47 27 μg/dos	0		-	- mRNA-1647 - mRNA-1647	8.9 µg/dose		
Group) 3 - IIIKINA-10	147 27 μg/dos	e		Group 4	- IIIKINA-104/	89 μg/dose		
Group	/				Day (F	rom/To)	1, 20		_
Sex		-9/1	1/8	8/15	15/22	22/29	29/36	36/43	43/50
							all leading		
lM	Mean	29.79	32.44	33.35	34.38	35.31	35.08	35.83	34.50
	SD	2.04	2.32	2.78	2.09	1.99	1.90	1.89	0.60
	N	15	15	15	34.38 2.09 15 33.52 1.61 10 -2.50	ads) or	15	15	4
2M	Mean	30.26	31.32	33.02	33.52 1.61 -2.50 31.72 0.94	34.60	33.55	33.85	
.1.1	SD	0.71	0.57	1.67	1.61	1.11	1.67	1.63	
	N	7	10	10	10 0113	× 10	10	10	
	%Diff G1	1.58	-3.45	-0.98	-2.50	-2.02	-4.36	-5.52	
				Ø	11. 30 40				
3M	Mean	27.69	28.56	31.18	31.72	32.89	31.89	33.51	
	SD	0.76	1.51	1.13	0.94		1.40	1.62	
	N	7	10	10	10	10	10	10	
	%Diff G1	-7.05	-11.96	31.18 1.13 10 -6.50 35.05	-7.74	-6.86	-9.09	-6.47	
4M	Mean	30.79	30.11	35.05	33.24	36.78	33.65	36.55	34.88
1171	SD	0.91	1.13	1.28	1.14	1.16	0.80	1.52	0.44
	N	15	15 N	1.28 1.5 5.10	15	15	15	15	5
	%Diff G1	3.36	-7.190	5 10	-3.32	4.15	-4.09	2.03	1.10

Group 2 - mRNA-1647	8.9	μg/dose
Group 4 - mRNA-1647	89	μg/dose

Table	4		, Varie
Sumn	nary of Fo	ood Consumption ((g/animal/day) Group 2 mPNA 1647 8.0 ug/daga
Group 3	l - Referenc 3 - mRNA-1	e Item .647 27 μg/dose	Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose
Group / Sex		Day (From/To) 50/56	ad super 201
1M	Mean	34.23	
	SD	1.35	
	N	4	apply of the second of the sec
2М	Mean		En al of the
∠1 V1	SD		20° 2110 1200
	N		oliko jijs akolik
	%Diff G1		S. F. VO.
03.6	Mass		84, 95, 40
5M	viean		Sill EC
	N		alte all
	%Diff G1		
4M	Mean	37.18	X ALCOUNTY
	SD	0.66	20,314
	N	5	EUR, ude
	%Diff G1	8.63	16 4 N
5002034	This do	Junent cannot be us	Group 2 - mRNA-1647 8.9 µg/dose Group 4 - mRNA-1647 8.9 µg/dose

Table 4 Summary of Food Consumption (g/animal/day)

Table	e 4							Test Facility	Page 6 Study No. 500203
Sumi	mary of Foo	od Consump	otion (g/anima	ıl/day)				501	
Groun	1 - Reference	Item			Group 2	2 - mRNA-1647	8.9 ug/dose	Olis	
-		647 27 μg/dose	e		-	4 - mRNA-1647		, N	
	,					(77)	etio		
Group / Sex	/	-9/1	1/8	8/15	Day (F 15/22	rom/To) 22/29	29/36	36/43	43/50
		2/-2	1,0	<i>0,</i> 10	10,22		and anily	5 67 15	
	3.5	22.04	22.02	22.15	22.00	22.24.0	0000	22.10	22.20
lF	Mean	22.94	23.02	23.17	23.99	23.81	23.97	23.18	23.28
	SD	1.47	1.47	1.43	1.66	1,400	1.13	1.49	1.20
	N	12	15	15	15	1.40	15	15	5
F	Mean	22.25	23.38	24.17	24.37	24.28	24.50	23.83	
	SD	1.14	0.61	0.88	1.65	2.03	1.12	1.44	
	N	10	10	10	20	10	10	10	
	%Diff G1	-3.01	1.56	4.33	23.99 1.66 15 24.37 1.65 10 1.60 24.19 1.12	1.96	2.20	2.80	
F	Mean	22.13	23.37	24.13 0.91 10 4.16 23.57 2.29	24 19	24.72	24.45	24.64	
Г	SD	0.23	0.60	0.01	4 12	1.31	1.57	1.04	
	N	7	10	10	10	10	10	10	
	%Diff G1	-3.54	1.52	4 16	0.85	3.81	1.99	6.30	
	, ULJ III (J I	-J.J .	1.52	ary allo	0.05	3.01	1.//	0.50	
F	Mean	21.65	21.89	23.57	24.00	23.84	23.63	24.17	23.08
	SD	1.44	1.81	2.29	1.91	2.10	2.15	2.45	0.71
	N	15	الم 15	15	15	15	15	15	5
	%Diff G1	-5.62	-4.92	1.76	0.06	0.11	-1.45	4.29	-0.86

- 4401	e 4		Test Facility Study No. on (g/animal/day) Group 2 - mRNA-1647 8.9 μg/dose
Sumi	mary of Fo	od Consumptio	on (g/animal/day) Group 2 mPNA 1647 8.0 mg/daga
Group	3 - mRNA-1	e item 647 27 μg/dose	Group 4 - mRNA-1647 89 μg/dose Group 4 - mRNA-1647 89 μg/dose
Group :	l	Day (From/To) 50/56	Group 2 - mRNA-1647 8.9 µg/dose Group 4 - mRNA-1647 8 - mg/dose Group 4 - mg/dose Grou
1F	Mean	25.18	"iol color
	SD N	0.66 5	adjest, 13 s
2F	Mean		
	SD		100° E3110120°
	N %Diff G1	 	Cashinol Oks
3F	Mean		or of the
	SD N		it of the second
	%Diff G1		ay modified
4F	Mean	24.84	of all coll
	SD N	0.77 5	Supple det
	%Diff G1	-1.35	1,60 g/m

Table 5 **Summary of Body Temperature Values**

							Test Facility
							idilo
Tabl	e 5						13/10
Sum	mary of Ro	dy Tempera	tura Values				Test Facility
	•	• •	ture varues				ONS
	ıp 1 - Referen				Group 2 - mRNA	A-1647 8.9 μg/dos	30 Cal
Grou	ıp 3 - mRNA-	-1647 27 μg/do	se		Group 4 - mRNA	A-1647 89 μg/dos	ies)
	4					761	201
Paran	Doug	Temp				any	
	°C					No Mo	
Group	/		Day 1	Day 2		y 43	Day 44
Sex		pr	p		pr	SP SP	
1 M	Mean	36.24	35.26	37.45	36.23		36.91
	SD	0.44	0.88	0.50	36.23	36.79 0.56	0.65
	N	15	15	15	0.15;(01)(0)	15	14
					100 :00 :00 is		
2M	Mean	36.82b	35.99	36.92d	36.89d	36.66	36.47
	SD	0.25	0.52	0.24	0.84	0.49	0.41
	N avp:m.c.t	10	10	10	790	10	10
	%Diff G1	1.60	2.07	-1.42	1.81	-0.36	-1.20
3M	Mean	36.64	36.66e	37.13	0.41 15 36.89d 0.84 10 1.81 37.97f 0.60	37.60e	36.99
	SD	0.26	1.06	37.13 0.41	0.60	0.66	0.28
	N	10	10	10 10	10	10	10
	%Diff G1	1.10	3.97	37.47 0.55	4.79	2.19	0.21
4M	Mean	36.61	38.05f	37.47	36.81d	37.53e	37.29
→1AT	SD	0.52	1 08	0.55	0.56	0.52	0.73
	N N	15	1.08 15 7.90	15	15	15	15
	%Diff G1	1.01	07 90.50	0.05	1.60	2.01	1.01
	70DIII 01	1.01	500	0.05	1.00	2.01	1.01

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunn) $d=p \le 0.05, e=p \le 0.01, f=p \le 0.001$ (Dunnett)

Table 5 **Summary of Body Temperature Values**

Tabl		dy Tompon	Anno Volvog				Test Facilit	Page 66 y Study No. 5002034
	•	dy Tempera	ture values		Correct 2 and DNI	A 1647 9.0/1-	:015	
	up 1 - Reference	ce item 1647-27 µg/do			Group 4 mRN	A-1647 8.9 μg/do	CP -	
Grot	ль э - шкиу А -	10 1 1 21 μg/α0	200		Group 4 - IIIKN	A-1647 89 μg/dos	F 2	
Param	neter: Body °C	Тетр				and any	1221 1221	
Group	1		Day 1	Day 2	Day 3	Sign Sept I	Day 43	Day 44
Sex		pr	p			ilo Spr	p	
					die	20 12		
1F	Mean SD	37.32 0.41	36.25 0.50	37.62	26k	0.61	37.04 0.58	37.39 0.71
	N N	15	15	0.33	8 000	15	15	15
	IN	13	13	13	200 - All 1200	13	13	13
2F	Mean	37.59	36.79a	37.37	110.11201011	37.98	37.31	37.58
	SD	0.42	0.41	0.32	"HO 70.	0.59	0.60	0.57
	N	10	10	10	9/2 40-	10	10	10
	%Diff G1	0.72	1.48	-0.66	()	-0.07	0.73	0.52
				"Kerri K	7			
3F	Mean	37.50	36.87b	37.67		38.43	37.78b	37.88
	SD	0.47	0.54	0.35		0.57	0.46	0.74
	N	10	10	10		10	10	10
	%Diff G1	0.48	1.70	Q ^{0:13}		1.11	2.00	1.32
4F	Mean	37.64	37.55c	10 0.13 38.56c 0.53	37.55	37.77	38.59c	38.12b
	SD	0.51	0.44	0.53	0.48	0.74	0.34	0.57
	N	15	0.44 ST 11/10 15 S 3.59 SE 11/10	15	15	15	15	15
	%Diff G1	0.86	3.59	2.50		-0.63	4.18	1.96

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

Table 6
Summary of Hematology Values: Day 44

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose

Group /							7.2	
Group / Sex		WBC 10^3/uL	NEUT 10^3/uL	LYMPH 10^3/uL	MONO 10^3/uL	EOS 10^3/uL	BASO 10^3/uL	LUC 10^3/uL
		10 3/uL	10 5/uL	10 5/uL	10 3/uL	10 5/uL	TO S/UL	10° 5/uL
1M	Mean	10.570	1.595	8.402	0.303	0.108	0.020	0.138
	SD	3.788	0.794	3.157	0.067	0.043	0.013	0.063
	N	10	10	10	10	000	10	10
2M	Mean	10.776	2.920	7.017	0.236	0.277b	0.020	0.304e
	SD	1.208	0.957	1.092	0.070	0.072	0.007	0.142
	N	10	10	10	مان 10 مراد	10	10	10
	%Diff G1	1.949	83.072	-16.484	-22.112	156.481	0.000	120.290
3M	Mean	14.091	6.990f	6.259	0,216	0.301b	0.023	0.304e
J1V1	SD	2.499	1.908	1.840	0.114	0.068	0.009	0.104
	N	10	10	10	10	10	10	10
	%Diff G1	33.311	338.245	-25.506	-28.713	178.704	15.000	120.290
4M	Mean	18.827c	11.493f	6.487	0.188d	0.413c	0.023	0.251
1112	SD	3.862	2.497	1.959	0.098	0.147	0.013	0.092
	N	10	10	2010	10	10	10	9
	%Diff G1	78.117	620.564	-22.792	-37.954	282.407	15.000	81.965

Significantly different from control group 1 value : $a=p\le0.05,b=p\le0.01,c=p\le0.001$ (Dunn) $d=p\le0.05,e=p\le0.01,f=p\le0.001$ (Dunnett)

Table 6 **Summary of Hematology Values: Day 44**

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 µg/dose

Group /		RBC	HGB	НСТ	MCV	мсн	MCHC	RDW
Sex		10^6/uL	g/dL	%	fL(um3)	pg	g/dL	%
1M	Mean	7.682	13.69	41.38	53.87	17.84	33.10	12.70
1141	SD	0.252	0.35	1.29	1.50	0.60	0.49	0.66
	N	10	10	10	10	00	10	10
2M	Mean	7.817	13.59	41.54	53.16	17.41	32.73	13.05
	SD	0.290	0.36	1.05	1276	0.67	0.39	0.43
	N	10	10	10	ما 10 زاد	10	10	10
	%Diff G1	1.757	-0.73	0.39	1.32	-2.41	-1.12	2.76
3М	Mean	7.590	13.30	40.50	53,36	17.51	32.83	13.46b
	SD	0.228	0.41	1.32	0.98	0.31	0.27	0.52
	N	10	10	10	10	10	10	10
	%Diff G1	-1.198	-2.85	-2.43	-0.95	-1.85	-0.82	5.98
4M	Mean	7.900	13.93	42.58	53.88	17.66	32.74	13.82c
	SD	0.237	0.45	1.57	0.89	0.30	0.45	0.43
	N	10	10	20	10	10	10	10
	%Diff G1	2.838	1.75	2.90	0.02	-1.01	-1.09	8.82

Table	e 6						est Facility Study No
Group	mary of He 1 - Reference 3 - mRNA-16	matology Val : Item 647 27 μg/dose	lues: Day 44	Gı Gı	roup 2 - mRNA-1647 roup 4 - mRNA-1647	8.9 μg/dose 89 μg/dose	50
Group . Sex	/	PLT 10^3/uL	RETIC 10^9/L			and amber 2011	
1M	Mean SD N	1078.6 95.1 10	220.08 27.59 10		oplication	Seli	
2M	Mean SD N %Diff G1	1043.8 132.4 10 -3.2	RETIC 10^9/L 220.08 27.59 10 223.42 31.08 10 1.52 213.30 25.80 10 -3.08 218.49 26.57 10 -0.72	na cutho	isation 2007 or		
3M	Mean SD N %Diff G1	1059.2 117.1 10 -1.8	213.30 25.80 10 -3.08	Marketing & P			
4M	Mean SD N %Diff G1	1063.1 73.4 10 -1.4	218.49 26.57 10 -0.72	Sedim			
500203	4	nentcannoth	-0.72 SUN JINGE				

Table 6
Summary of Hematology Values: Day 44

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose

_							7,00	
Group Sex	,	WBC 10^3/uL	NEUT 10^3/uL	LYMPH 10^3/uL	MONO 10^3/uL	EOS 10^3/uL	BASO 10^3/uL	LUC 10^3/uL
						.0	76,	
1F	Mean	6.541	0.724	5.498	0.151	0.069	0.010	0.087
	SD	1.905	0.338	1.893	0.058	0.022	0.005	0.039
	N	10	10	10	10	000	10	10
2F	Mean	7.919	3.320	4.026	0.126	0.275b	0.008	0.166
	SD	1.209	0.645	0.880	0.061	0.057	0.006	0.100
	N	10	10	10	ما الله الله	10	10	10
	%Diff G1	21.067	358.564	-26.773	-16.556	298.551	-20.000	90.805
3F	Mean	9.060a	4.490c	3.996	0,110	0.272b	0.009	0.181
-	SD	1.455	0.983	0.772	0.039	0.122	0.003	0.085
	N	10	10	10	10	10	10	10
	%Diff G1	38.511	520.166	-27.319	-27.152	294.203	-10.000	108.046
4F	Mean	11.735c	6.434c	4.555	0.102	0.451c	0.012	0.176
	SD	3.029	1.624	1.495	0.036	0.265	0.009	0.105
	N	10	10	2010	10	10	10	10
	%Diff G1	79.407	788.674	-17.152	-32.450	553.623	20.000	102.299

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunn)

Table 6 **Summary of Hematology Values: Day 44**

Group 3 - mRNA-1647 27 µg/dose

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 µg/dose

iroup / ex		RBC	HGB	НСТ	MCV	MCH	MCHC	RDW
EX.		10^6/uL	g/dL	%	fL(um3)	pg	g/dL	%
lF	Mean	7.102	12.75	38.01	53.50	17.98	33.56	11.51
lr	SD	0.224	0.44	1.31	0.89		0.21	0.44
	N N	10	10	10	10	0.34	10	10
2F	Mean	6.916	12.51	37.43	54.11	18.12	33.47	11.89
21	SD	0.302	0.63	1.86	0.91	0.38	0.60	0.55
	N	10	10	10	1)10 all a	10	10	10
	%Diff G1	-2.619	-1.88	-1.53	D. 1111	0.78	-0.27	3.30
				eil eil				
3F	Mean	6.960	12.69	37.90	54,53	18.26	33.47	12.19a
	SD	0.491	0.86	2.58	1.52	0.62	0.57	0.62
	N	10	10	10	10	10	10	10
	%Diff G1	-1.999	-0.47	-0.29	1.93	1.56	-0.27	5.91
4F	Mean	7.176	13.03	38.69	53.92	18.19	33.69	12.79c
	SD	0.274	0.37	1.25	0.99	0.31	0.50	0.49
	N	10	10	10	10	10	10	10
	%Diff G1	1.042	2.20	1.79	0.79	1.17	0.39	11.12

Table 6 **Summary of Hematology Values: Day 44**

1 - Reference 3 - mRNA-16	Item 547 27 μg/dose	ues: Day 44	Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose
/	PLT 10^3/uL	RETIC 10^9/L	and anyer
Mean	1060.4	185.68	ion certification
SD	172.2	23.56	::(2,13)
N	10	10	applion
Mean	1019.1	196.20	200,000
SD	100.9	32.57	Operation 100
N	10	10	out of the character of
%Diff G1	-3.9	5.67	Ma. Sithe No.
Mean	971.1	218.11	0,00,7
SD	95.1	36.36	CHILLE O
N	10	10	The Car
%Diff G1	-8.4	17.47	A Missio,
Mean	868.1b	198.61	× 41, 30,
SD	102.0	36.03	201, 14
N	10	10	× %0,
%Diff G1	-18.1	6.96	The state of the s
•	Mean SD N Mean SD N Mean SD N Moiff G1 Mean SD N %Diff G1 Mean SD N %Diff G1	1 - Reference Item 3 - mRNA-1647 27 μg/dose PLT 10^3/uL Mean 1060.4 SD 172.2 N 10 Mean 1019.1 SD 100.9 N 10 %Diff G1 -3.9 Mean 971.1 SD 95.1 N 10 %Diff G1 -8.4 Mean 868.1b SD 102.0 N 10 %Diff G1 -18.1	PLT RETIC 10^3/uL 10^9/L Mean 1060.4 185.68 SD 172.2 23.56 N 10 10 Mean 1019.1 196.20 SD 100.9 32.57 N 10 10 %Diff G1 -3.9 5.67 Mean 971.1 218.11 SD 95.1 36.36 N 10 10 %Diff G1 -8.4 17.47 Mean 868.1b 198.61 SD 102.0 36.03 N 10 10

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

Table 6 **Summary of Hematology Values: Day 57**

Table 6						Т	Cest Facility Station
ummary o	f Hematology Val	lues: Day 57					ns or Vo
Group 1 - Refe	rence Item			Group 4 -	mRNA-1647 89	μg/dose	,
Group / Sex	WBC 10^3/uL	NEUT 10^3/uL	LYMPH 10^3/uL	MONO 10^3/uL	EOS 10^3/uL	BASO 10^3/uL	LUC 10^3/uL
M Mean	9.998	2.120	7.315	0.288	0.133 0.043	0.015	0.125
SD N	2.902 4	1.787 4	1.616 4	0.154 4	4	0.006 4	0.090 4
Mean SD	10.702 0.998	1.342 0.266	8.692 0.934	0.384	0.130 0.057	0.016 0.005	0.138 0.053
N %Diff	5	5 -36.698	5 18.824	33.565	5 -1.887	5 6.667	5 10.400

Table 6 **Summary of Hematology Values: Day 57**

							T (1)	
Group .	/						32.20	
Sex		RBC	HGB	HCT	MCV	MCH	MCHC	RDW
		10^6/uL	g/dL	%	fL(um3)	pg	g/dL	%
	Maan	7.042	12.62	40.00	<i>5</i> 2 10	17.20	0 22 22	10.72
1M	Mean	7.843	13.63	40.90	52.18	17.38	33.33	12.73
	SD	0.207	0.17	0.89	0.67	(C) (S)	0.63	0.57
	N	4	4	4	4	004	4	4
4M	Mean	7.656	13.36	41.00	fL(um3) 52.18 0.67 4 53.54a 0.68 5 2.62	MCH pg 17.38 0.41 4 17.48 0.40 5 0.60	32 64	14.60b
+1V1	SD	0.250	0.33	1.16	0.68	0 40	0.40	0.61
	N N	5	5	5	42,300	5	5	5
	%Diff G1	-2.378	-1.94	0.24	8) 282 A	0.60	-2 06	14.73
	/0DIII G1	-2.576	-1,,,,	0,24	Q. 12.02	0.00	-2.00	14.75
				⊘`	7.0. 4			
Signif	ticantly differed	nt from control g	roup 1 value :a=	p≤0.05,b=p≤0.01	i,c=p <u>≤</u> 0.001 (T-tes	t)		
				and dillage	1,c=p≤0.001 (T-tes			
				'SIL'SOD				
				or Ro				
			101	5 701				
			60,,	ILO				
			7,009	·				
			660 720					
			113 160					
		, 6	S. S.					
		201						
		alli						
		a' Co						
500203	4	rell.						
500205	·	.C.						
	2003							
	.5							
	/Win							
	*							

Page 7 Test Facility Study No. 500203 Table 6 Summary of Hematology Values: Day 57 Group 1 - Reference Item Group 4 - mRNA-1647 89 μg/dose Plan Group 4 - mRNA-1647 89 μg/dose Plan Group 4 - mRNA-1647 89 μg/dose Howard 105-3 nd. 105-91. N 4 4 4 M Mean 105-6 265-30a SD 119-7 32-08 N 5 5 5 %/Diff GI 10.7 23-61 Significantly different from control group 1 value :a=p=0.05,b=p=0.01,e=p=0.001 (T-test)	Tabl	e 6			gilati
Group 1 - Reference Item Group 4 - mRNA-1647 89 μg/dose Here is a second of the property of	Sum	mary of He	ematology Va	lues: Day 57	of No
Group / Sex PLT RETIC 10^3/uL 10^9/L 1M Mean 999.0 214.63 SD 135.9 18.22 N 4 4 4M Mean 1105.6 265.30a SD 119.7 32.68 N 5 5	Group	1 - Reference	e Item	in a contract of the contract	Group 4 - mRNA-1647 89 μg/dose
Group / Sex PLT RETIC 10^3/uL 10^9/L 1M Mean 999.0 214.63 SD 135.9 18.22 N 4 4 4M Mean 1105.6 265.30a SD 119.7 32.68 N 5 5					etiens.
1M Mean 999.0 214.63 SD 135.9 18.22 N 4 4 4M Mean 1105.6 265.30a SD 119.7 32.68 N 5 5	Group Sex	/	PLT 10^3/uL	RETIC 10^9/L	and amber 20th
4M Mean 1105.6 265.30a SD 119.7 32.68 N 5 5	1M	Mean SD N	999.0 135.9 4	214.63 18.22 4	olication septe
	4M	Mean SD N	1105.6 119.7 5	265.30a 32.68 5	The base of the second of the
%Diff G1 10.7 23.61		SD N %Diff G1	119.7 5 10.7	32.68 5 23.61	orna, europaisation 20dal 200
	2-6				
* and collection	2-8			્રં	NA CATISTIC
EURPORT and Individual Control of the Control of th	3-8			cup of a	Regulation of the second of th
ad to support any main tion				ed to support a	A Redulation
Se Led to Support any main and production of the control of the co				e used to support of	Regulative Commence of the Com
and be used to support any main and the used under Redulation			anot	pe used to support a	Regulative Commence of the Com
rt canot be used to support any main and the used to support and the used to support any main and the used to support and the used to support any main and the used to support and the used to support any main and the used to support any main and the used to support any main and the used to support and the used to support and the used to support and the used to s			nt cannot	sused to support to	Regulative Commence of the Com

Table 6 **Summary of Hematology Values: Day 57**

Table (Test Facility Study le 6 nmary of Hematology Values: Day 57											
Summ	ary of Her	natology Valı	ues: Day 57					Sof				
Group 1	- Reference	Item			Group 4 - 1	mRNA-1647	89 μg/dose)*				
							tie, o					
Group / Sex		WBC 10^3/uL	NEUT 10^3/uL	LYMPH 10^3/uL	MONO 10^3/uL	EOS 10^3/uL	BASO 10^3/uL	LUC 10^3/uL				
lF	Mean	4.132	0.892	2.970	0.152	0.066	0.000	0.052				
	SD	1.035	0.265	0.905	0.063	0.011	0.000	0.029				
	N	5	5	5	5	36630U	5	5				
4F	Mean	4.590	0.844	3.530	0.090	0.080	0.002	0.042				
	SD	1.866	0.606	1.391	0.056	0.027	0.004	0.022				
	N	5	5	5	113,420,10	5	5	5				
	%Diff G1	11.084	-5.381	18.855	-40.789	21.212		-19.231				

Table 6 **Summary of Hematology Values: Day 57**

HGB g/dL 12.60				10,00	
g/dL	HCT	MCV	MCH	MCHC	RDW
12 60			pg	g/dL	%
12 60			\ \dagger_{\infty}	XO.	
	37.38	53.92	18.14	33.64	11.48
0.58	1.41	1.19	0.61	0.63	0.41
5	5	5	003	5	5
12.46	36.76	fL(um3) 53.92 1.19 5 53.68 1.36 5 -0.45 L.c=p≤0.001 (T-test	pg 18.14 0.61 5 18.20 0.33 5 0.33	33.88	12.66b
0.47	1.30	1.36	0.33	0.54	0.47
5	5	(37:50,0	5	5	5
-1.11	-1.66	-0.45 O	0.33	0.71	10.28
	-10	10 20 10			
oup 1 value :a=	-p≤0.05,b=p≤0.01	l,c=p <u>≤</u> 0.001 (T-test	:)		
used to supp	inger,				
				oup 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-test)	

	- -			Natio
Sum: Group	mary of He	ematology Val	lues: Day 57	Group 4 - mRNA-1647 89 μg/dose
Group /	/	PLT 10^3/uL	RETIC 10^9/L	- ad any export
1F	Mean SD N	1044.0 139.5 5	163.78 16.45 5	adjication are often
4F	Mean SD N %Diff G1	1105.2 80.9 5 5.9	169.54 21.05 5 3.52	- a.e.lipopa.e.lipopalonon
				Test Facility Study No. 50 Group 4 - mRNA-1647 89 μg/dose
			dro supp	inder Re
		anoti	o Relegis	
500203	4	Menticali		

Table 7 **Summary of Coagulation Values: Day 44**

Group / Sex		PT sec	APTT sec	FIB mg/dL 302.6 26.0 10 514.2c 36.4 10 69.9 576.2c 53.6 10 90.4	Group 2 - 1 Group 4 - 1	
1M	Mean	17.61	15.50	302.6		
	SD N	0.86 10	0.75 10	26.0 10		OPIIC
2M	Mean	17.55	16.21	514.2c	7.61,100	.00,
	SD	0.54	0.77	36.4	,08.63il	
	N	10	10	10	an on on) -
	%Diff G1	-0.34	4.58	69.9	is office to	
3M	Mean	17.51	17.62c	576.2c	907	
	SD	0.74	0.69	53.6	(E)	
	N	10	10	10		
	%Diff G1	-0.57	13.68	90.4		
1M	Mean	17.09	18.79c	645.70		
	SD	1.15	1.07	56.6		
	N	10	10	112.4		
	%Diff G1	-2.95	21.23	113.4		

Table 7 **Summary of Coagulation Values: Day 44**

Group / Sex	,	PT sec	APTT sec	FIB mg/dL 252.0 33.1 10 416.3c 50.2 10 65.2 473.7c 59.3 10 88.0 \$26.3c 73.5
1F	Mean	17.13	14.97	252.0
	SD	0.76	1.58	33.1
	N	10	10	10
2F	Mean	17.44	17.99c	416.3c
	SD	0.78	1.24	50.2
	N	10	10	10
	%Diff G1	1.81	20.17	65.2
3F	Mean	16.70	17.80b	473.7c
	SD	0.95	2.09	59.3
	N	10	10	10
	%Diff G1	-2.51	18.90	0.88
4F	Mean	16.72	18.35c	526.36
	SD	0.63	1.41	73.5
	N	10	10	× × 10
	%Diff G1	-2.39	22.58	108.8

Group 1 - Group / Sex	ry of Coa	gulation Val	lues: Day 57				COLVO		
Group 1 - Group / Sex	Reference I	tem	ides. Day 37						
Group / Sex					Group 4 - mRNA-1647 89 μg/dose				
Group / Sex							eters		
1M		PT sec	APTT sec	FIB mg/dL		and and	10 10 10 10 10 10 10 10 10 10 10 10 10 1		
	Mean SD N	18.10 0.77 4	16.08 0.22 4	288.5 22.5 4		adjication septe			
4M	Mean SD N %Diff G1	18.38 0.81 5 1.55	15.96 0.69 5 -0.72	274.4 11.5 5 -4.9	eliopaen odolo	00,01			
5002034	ر الم	nent camot '	suppleased	ort any marke outation			Test Facility Study Nose ose Norwalia in Maria i		

Table 7	7				Test Facility Study No. 500
Summ	arv of Coa	gulation Va	lues: Day 57		Of Jo
Group 1	- Reference	Item	acor zaj c.		Group 4 - mRNA-1647 89 μg/dose
					et 2
Group / Sex		PT sec	APTT sec	FIB mg/dL	and amber 20
1F	Mean SD N	17.74 0.64 5	15.64 0.96 5	195.4 19.9 5	adjication septie
4F	Mean SD N %Diff G1	17.98 1.00 5 1.35	15.00 1.08 5 -4.09	218.8 38.5 5 12.0	Fe Test Facility Study No. 50 Group 4 - mRNA-1647 89 μg/dose Group 4 - mRNA-1647 89 μg/dose Group 4 - mRNA-1647 89 μg/dose
					Sau 40

Table 8 **Summary of Clinical Chemistry Values: Day 44**

Group 2 - mRNA-1647 8.9 μ g/dose Group 4 - mRNA-1647 89 µg/dose

Group / Sex		AST	ALT	ALP	GGT	CK	TBIL	UREAN
JOA		U/L	U/L	U/L	U/L	U/L	mg/dL	mg/dL
1M	Mean	99.8	40.0	113.1	2.0	560.1:0	0.069	13.2
1141	SD	21.7	5.3	21.4	0.0	424.7	0.021	2.6
	N	10	10	10	10	010	10	10
2M	Mean	98.7	40.8	114.7	2.0 0.0 10 0.0 2.0 0.0	500.5	0.073	15.0
	SD	15.0	6.2	14.2	0.0	181.9	0.023	2.5
	N	10	10	10	J10 (1)	10	10	10
	%Diff G1	-1.1	2.0	1.4	0.0	-10.6	5.797	13.6
3M	Mean	97.2	44.3	119.9	2,0	447.2	0.082	16.2a
	SD	34.3	12.6	30.2	0.0	256.7	0.023	1.9
	N	10	10	10	10	10	10	10
	%Diff G1	-2.6	10.8	10 6.0 211	0.0	-20.2	18.841	22.7
4M	Mean	102.7	38.7	121.2	2.0	495.6	0.082	13.8
	SD	18.5	3.7	16.6	0.0	265.4	0.021	1.7
	N	10	10	₹ <mark>%</mark> 10	10	10	10	10
	%Diff G1	2.9	-3.3	7.2	0.0	-11.5	18.841	4.5

Table 8 **Summary of Clinical Chemistry Values: Day 44**

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 µg/dose

Group 3 - mRNA-1647 27 µg/dose

Group / Sex		CREAT	GLUC	CHOL	TRIG	TPROT	ALB	GLOB
		mg/dL	mg/dL	mg/dL	mg/dL	g/dL	g/dL	g/dL
1M	Mean	0.34	188.2	68.1	88.8	5.77	3.64	2.13
1141	SD	0.05	29.0	16.2	38.8	0.21	0.13	0.19
	N	10	10	10	10	20	10	10
2M	Mean	0.37	194.6	74.9	70.6 38.1 10 -20.5 63.1 15.8 10	05.88	3.38c	2.50c
	SD	0.05	44.0	17.1	38.1	0.21	0.18	0.12
	N	10	10	10	(1) 10 (I) D	10	10	10
	%Diff G1	8.82	3.4	10.0	38-1 10 -20.5	1.91	-7.14	17.37
3M	Mean	0.39	197.6	75.5	63,1	5.85	3.29c	2.56c
	SD	0.06	30.7	8.8	15.8	0.26	0.09	0.22
	N	10	10	10	10	10	10	10
	%Diff G1	14.71	5.0	10 10.9 71.8 71.8	-28.9	1.39	-9.62	20.19
4M	Mean	0.39	178.8	71.8	68.7	5.94	3.27c	2.67c
	SD	0.03	31.4	15.1	24.2	0.26	0.15	0.20
	N	10	10	№10	10	10	10	10
	%Diff G1	14.71	-5.0	5.4	-22.6	2.95	-10.16	25.35

Table 8 **Summary of Clinical Chemistry Values: Day 44**

Group 2 - mRNA-1647 8.9 μ g/dose Group 4 - mRNA-1647 89 µg/dose

Group / Sex		A/G	CA	PHOS	NA	K	S. Car
		ratio	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L
1M	Mean	1.72	10.23	8.02	140.2	5.19	100.7
1141	SD	0.18	0.30	0.81	1.3	0.46	1.2
	N	10	10	10	10	70	10
2M	Mean	1.37c	10.20	7.80	139.8	5.49	100.1
	SD	0.11	0.29	0.45	(1)2	0.36	1.7
	N	10	10	10	(1)10 (i) A	⁵⁾ 10	10
	%Diff G1	-20.35	-0.29	-2.74	(A) -	5.78	-0.6
3M	Mean	1.29c	10.42	7.96	139,4	5.67a	100.1
	SD	0.11	0.24	0.68	1.2	0.39	1.6
	N	10	10	10	10	10	10
	%Diff G1	-25.00	1.86	-0.75	-0.6	9.25	-0.6
4M	Mean	1.22c	10.42	8.36	140.3	5.76b	100.4
	SD	0.11	0.40	0.71	1.3	0.21	1.4
	N	10	10	10	10	10	10
	%Diff G1	-29.07	1.86	4.24	0.1	10.98	-0.3

Table 8 **Summary of Clinical Chemistry Values: Day 44**

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 µg/dose

Sex		AST	ALT	ALP	GGT	CK	TBIL	UREAN
		U/L	U/L	U/L	U/L	U/L	mg/dL	mg/dL
1F I	Mean	89.7	36.7	62.8	2.0	365.5	0.064	14.2
	SD	23.0	7.6	16.7	0.0	208.8	0.019	2.0
	N	10	10	10	10	3000	10	10
2F I	Mean	100.1	38.6	68.1	2.9 EV	427.6	0.077	15.5
	SD	25.8	8.6	11.6	(0.0	243.6	0.018	3.0
]	N	10	10	10	J10 (1)	x 10	10	10
Ģ	%Diff G1	11.6	5.2	8.4	7.0010.0	17.0	20.313	9.2
3F 1	Mean	105.0	40.1	64.6	2.0	477.4	0.085	15.7
	SD	40.5	16.0	18.8	0.0	317.6	0.025	1.8
]	N	10	10	10	10	10	10	10
ç	%Diff G1	17.1	9.3	10 2.9 all	0.0	30.6	32.813	10.6
4F 1	Mean	106.6	38.3	74.4	2.0	500.5	0.087	17.5a
5	SD	25.0	10.8	12.1	0.0	282.0	0.025	2.7
]	N	10	10	0 010	10	10	10	10
Ç	%Diff G1	18.8	4.4 5	18.5	0.0	36.9	35.938	23.2

Table 8
Summary of Clinical Chemistry Values: Day 44

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 μg/dose_×

							or av	
Group /		CREAT	GLUC	CHOL	TRIG	TPROT	ALB	GLOB
Sex		mg/dL	mg/dL	mg/dL	mg/dL	g/dL	g/dL	g/dL
						700	,0,0	
1F	Mean	0.42	209.9	82.2	79.8	6.51	4.54	1.97
	SD	0.04	37.4	13.1	62.9	0.41	0.27	0.18
	N	10	10	10	10	000	10	10
2 F	Mean	0.40	192.0	88.1	47.3	6.32	4.02c	2.30c
21	SD	0.05	24.9	17.3	A dillo	0.39	0.35	0.15
	N	10	10	10	Ulo di A	10	10	10
	%Diff G1	-4.76	-8.5	7.2	O -40.7	-2.92	-11.45	16.75
				ell	. ~ \(\)			
3F	Mean	0.42	181.3	85.5	57.7	6.40	4.07b	2.33c
	SD	0.06	23.2	13.9	14.9	0.16	0.21	0.12
	N	10	10	10	10	10	10	10
	%Diff G1	0.00	-13.6	4.0	-27.7	-1.69	-10.35	18.27
4F	Mean	0.45	182.3	× 76.5 0	56.4	6.35	3.93c	2.42c
4 T.	SD	0.05	20.2	15.2	17.2	0.22	0.24	0.15
	N	10	10	210	10	10	10	10
	%Diff G1	7.14	-13.1	-6.9	-29.3	-2.46	-13.44	22.84
				J				

Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Dunnett)

Table 8 **Summary of Clinical Chemistry Values: Day 44**

Group 2 - mRNA-1647 8.9 μg/dose Group 4 - mRNA-1647 89 µg/dose

Group /		A/G	CA	PHOS	NA	K	Sall CE
Sex		ratio	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L
1F	Mean	2.32	10.82	6.59	139.6	4.76	101.2
	SD	0.17	0.24	0.82	1.4	0.21	1.6
	N	10	10	10	10	20	10
2F	Mean	1.75c	10.65	6.90	140.2	4.99	101.8
	SD	0.18	0.39	0.71	Al all	0.34	1.5
	N	10	10	10	(1)10 (I) (A	²⁰ 10	10
	%Diff G1	-24.57	-1.57	4.70	0.4	4.83	0.6
3F	Mean	1.76c	10.78	7.05	140,5	4.96	101.5
	SD	0.16	0.30	0.64	1.3	0.32	2.7
	N	10	10	10	10	10	10
	%Diff G1	-24.14	-0.37	6.98	0.6	4.20	0.3
4F	Mean	1.64c	10.62	7.12	139.8	5.09	101.1
	SD	0.16	0.28	0.71	0.8	0.18	2.0
	N	10	10	10	10	10	10
	%Diff G1	-29.31	-1.85	8.04	0.1	6.93	-0.1

Table 8 **Summary of Clinical Chemistry Values: Day 57**

Group / Sex AST U/L ALT ALP U/L GGT U/L 1M Mean SD 11.5 97.8 40.5 120.0 2.0 SD 11.5 11.5 11.0 0.0	CK U/L 661.5 195.7 4 323.4a 119.2 5 -51.1	TBIL mg/dL 0.073	UREAN mg/dL
AST ALT ALP GGT U/L U/L U/L U/L Mean 97.8 40.5 120.0 2.0	CK U/L 661.5	mg/dL	
1M Mean 97.8 40.5 120.0 2.0	661.5 195.7	mg/dL 0.073	mg/dL
1M Mean 97.8 40.5 120.0 2.0	661.5	0.073	
IM Mean 97.8 40.3 120.0 2.0	195.7	0.5 0.073	17.0
	195.77	0.021	
SD 11.5 11.5 11.0 0.0	C'/ 0'/	0.021	3.2
N 4 4 4	004	4	4
N 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	323.4a	0.064	15.0
SD 14.7 4.3 18.0 0.0	119.2	0.009	2.9
N 5 5 5 5	5	5	5
%Diff G1 -21.0 0.7 -12.8	-51.1	-11.724	-11.8
Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-te	est)		
Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-te			
amot be use leas			
Co.			
5002024			
JUU2UJ4			
70 _C			
. 50			
This			

Table 8 **Summary of Clinical Chemistry Values: Day 57**

3roup /	,	CDEAT	CLUC	CHOL	TDIC	TDDOT	W. I.	GLOB
Sex		CREAT	GLUC	CHOL	1 KIG	IPROI _/at	Abb	
		mg/dL	mg/dL	mg/dL	mg/aL	g/aL	S gran	g/dL
1 M	Mean	0.33	188.8	81.0	mg/dL 107.8 34.2 4 98.2 33.1 3 -8.9	5.93	3.65	2.28
1141	SD	0.05	23.2	16.1	34.2	0.15	0.10	0.10
	N	4	4		4	1,00 V,2	4	4
						20/06		
4M	Mean	0.34	260.2	65.8	98.2	5.62a	3.60	2.02b
	SD	0.05	62.8	7.9	33.1	0.13	0.10	0.08
	N	5	5	5	98.2 © U 33.10 3110 33.10 3110	5	5	5
	%Diff G1	4.62	37.9		6.8°0, VOV	-5.15	-1.37	-11.21
					3, 40			
	icantiv differer	it trom control (
Signif	,	o nom condor g	group 1 value :a=]	p≤0.05,b=p≤0.01	,c=p≤0,001 (T-tes	TPROT g/dL 5.93 0.15 4 5.62a 0.13 5 -5.15		
Signif	,	w moni oonao i	group I value :a=	p<0.05,b=p<0.01	c=p≤0,001 (T-tes	it.)		

Table 8 **Summary of Clinical Chemistry Values: Day 57**

	/	A/G ratio	CA mg/dL	PHOS mg/dL	NA mmol/L	K mmol/L	CL/ mmol/L
1M	Mean	1.60	10.45	7.05	mmol/L 140.3 1.3 4 137.4a 1.5 5 -2.0	5.20 0.16 4 5.24 0.29 5 0.77	99.8
11/1	SD	0.08	0.26	0.41	1.3	0.16	2.2
	N	4	4	4	4	264 V.2	4
4M	Mean	1.80a	10.50	7.60	137.4a	5.24	98.8
	SD	0.10	0.56	0.42	1.5° ×10°	0.29	2.3
	N	5	5	5	113,120,0	5	5
	%Diff G1	12.50	0.48	7.80	13.57.50 VOK	0.77	-1.0
				Maike	on		
				Mailati			
				31,30			
			(16 500			
			1100	office s			
			10 SUPP	inder Res			
			sed to supply	inder Res			
		~	e Jeglenegel	inger been			
		o ^t .V	e Released	inder Res			
		annotic	e Leleuzell	inger been			
		at cannot b	e Released	inder Res			
5002034	4	nent camot b	e Leglegeed	inger been			
5002034	4 	ment cannot 's	se Released	inder Res			
5002034	4 :5 docu	nent camot b	e zeleasedi	inder Peo			
5002034	4 This docu	nerit cannot v	e Released	on Person	,c=p≤0,001 (T-test		

Table 8 **Summary of Clinical Chemistry Values: Day 57**

U/L U/L U/L U/L U/L U/L U/L U/L U/L mg/dL								et (1)	•
U/L U/L U/L U/L U/L U/L mg/dL	_	/	A COT	A.T. 75	ATD	COT	CIZ	2	IIDI 434
1F Mean 104.0 44.0 58.8 2.0 644.2 0.068 19.0 SD 14.5 7.5 10.9 0.0 186.0 0.016 3.0 N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Sex					GGT	CK	TBIL	UREAN
IF Mean 104.0 44.0 58.8 2.0 644.2 0.068 19.0 SD 14.5 7.5 10.9 0.0 186.0 0.016 3. N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5			U/L	U/L	U/L	U/L	U/L	mg/dL	mg/dL
SD 14.5 7.5 10.9 0.0 186.1 0.016 3. N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		Maon	104.0	44.0	50 0	2.0	644.2	0 068	10.6
N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	IF					2.0	196.4	0.006	
4F Mean 78.4b 36.4 74.2 2.0 213.0b 0.052 19.4 SD 5.0 4.4 21.1 0.0 64.2 0.013 2.1 N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5						0.0	100.10	0.010	
4F Mean 78.4b 36.4 74.2 2.0 213.0b 0.052 19.0 SD 5.0 4.4 21.1 0.0 64.2 0.013 2. N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		N	3	3	3	3	0620	3	3
SD 5.0 4.4 21.1 0.0 64.2 0.013 2.1 N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1E	Mean	78 4h	36.4	74.2	2000	213.0h	0.052	19.0
N 5 5 5 5 5 5 5 5 9/Diff G1 -24.6 -17.3 26.2 0.0 -66.9 -23.529 -3. Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-test)	41.					0.0	64.2	0.013	2.7
%Diff G1 -24.6 -17.3 26.2 0.00 -66.9 -23.529 -3. Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-test)						(97,18)	5	5	
Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,a=p≤0.001 (T-test) Significantly different from control group 1 value :a=p≤0.05,b=p≤0.001 (T-test)						Chianilo Op	-66.9	-23 529	-3.1
Significantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (T-test)						10. 111. V.			
5002034 This document cannot be used to support any part of the used to support any part of t					Mark	on			
5002034 This document cannot be used to support and the support of					" SULY COLLE				
5002034 This document cannot be used to supply the supply of the supply					or Ro				
5002034 This document calmot the used to set time This document calmot the used time This document calmot time T				191	5,76,				
5002034 This document cannot be used to be a seed to be a				S	TUC				
5002034 This document cannot be used by the like of t				7,000					
5002034 This document cannot be size all a second of the size all a se				SOUNE					
5002034 This document cannot be the				0 000					
5002034 This document canno			i.	D. K.					
5002034 This document call.			MO						
5002034 This document			Call						
5002034 This docume			ani						
This docu	500203	4	ine						
This do		C	>,						
This		90							
		Mis							

Table 8 **Summary of Clinical Chemistry Values: Day 57**

						40,201	
	CREAT	GLUC	CHOL	TRIG	TPROT	ALB	GLOB
	mg/dL	mg/dL	mg/dL	mg/dL	g/dL	g/dL	g/dL
Mean	0.44	195.2	82.4	135.2	6.52	4 68	1.84
			21.8	45 7	0.52	0.11	0.13
			5	5	130 V3	5	5
					20/01		
Mean	0.42	182.2	65.6	59.4a	6.12	4.30a	1.82
	0.04	38.5	8.7	3.0	0.41	0.30	0.15
	5	5	5	11/3, 1/20	5	5	5
%Diff G1	-4.55	-6.7	-20.4	-56.P	-6.13	-8.12	-1.09
cantly differer	nt from control g	group 1 value :a=r	o≤0.05,b=p≤0.01	,c=p≤0,001 (Wilc	oxon)		
	*~	se religion supp	inder				
	Carinot						
	SD N Mean SD N %Diff G1	SD 0.05 N 5 Mean 0.42 SD 0.04 N 5 %Diff G1 -4.55	SD 0.05 27.5 N 5 5 Mean 0.42 182.2 SD 0.04 38.5 N 5 5 %Diff G1 -4.55 -6.7	SD 0.05 27.5 21.8 N 5 5 5 Mean 0.42 182.2 65.6 SD 0.04 38.5 8.7 N 5 5 5 5 90 Moiff G1 -4.55 -6.7 -20.4 cantly different from control group 1 value :a=p≤0.05,b=p≤0.01	SD 0.05 27.5 21.8 45.7 N 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	SD 0.05 27.5 21.8 45.7 0.15 N 5 5 5 5 5 Mean 0.42 182.2 65.6 59.4a 6.12 SD 0.04 38.5 8.7 3.9 0.41 N 5 5 5 5 **Wolff G1 4.55 -6.7 -20.4 -56.0 -6.13 cantly different from control group 1 value :a=p≤0.05,b=p≤0.01,c=p≤0.001 (Wilcoxon)	SD 0.05 27.5 21.8 45.7 0.15 0.11 N 5 5 5 5 5 Mean 0.42 182.2 65.6 59.4a 6.12 4.30a SD 0.04 38.5 8.7 3.0 0.41 0.30 N 5 5 5 5 5 %Diff G1 -4.55 -6.7 -20.4 -56.1 -6.13 -8.12

Table 8
Summary of Clinical Chemistry Values: Day 57

Group 4 - mRNA-1647 89 µg/dose

Group	/						76.50
Sex		A/G	CA	PHOS	NA	K	CL
		ratio	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L
							D, 10,
1F	Mean	2.54	10.90	5.82	138.8	4.64	100.4
	SD	0.21	0.29	0.83	1.3	0.23	1.5
	N	5	5	5	5	35	5
						26 OL	
4F	Mean	2.36	10.56	6.56	138.0	4.58	100.2
	SD	0.15	0.42	1.10	100	0.31	1.6
	N	5	5	5	113, 120, 10	5	5
	%Diff G1	-7.09	-3.12	12.71	68 ON	-1.29	-0.2

Table 9 Summary of a1-acid Glycoprotein and a2-macroglobulin Values

Day 44 Males

Group 1 - Reference Item

Group 3 - mRNA-1647 27 μg/dose

Group 2 - mRNA-1647 8.9 μg/dose

Group 4 - mRNA-1647 89 µg/dose

	Summary	α1-acid Glycoprotein	α2-macroglobulin
Group	Information	μg/mL	μg/mL
			22.505
1	Mean	94.060	23.306
	SD	29.429	12.169
	N	10	102.
			100; 150° 01' L
2	Mean	257.432 C	105.194
	SD	43.395	68.816
	N	10	0,00,10
	% Diff (G1)	174	Ail (390
			aik ar
3	Mean	390.988 C	293.504 F
	SD	56.379	237.643
	N	10	10
	% Diff (G1)	316	1149
		316	
4	Mean	551.569 C	382.531 F
	SD	551.569 C 151.980 10 486	211.063
	N	10	10
	% Diff (G1)	486	1527

Significantly different from control group (Group 1) value: $A - P \le 0.05 \ B - P \le 0.01 \ C - P \le 0.001 \ (Dunnett)$ $D - P \le 0.05 \ E - P \le 0.01 \ F - P \le 0.001 \ (Dunn)$

Table 9 Summary of a1-acid Glycoprotein and a2-macroglobulin Values

Day 44 Females

Group 1 - Reference Item

Group 3 - mRNA-1647 27 μg/dose

Group 2 - mRNA-1647 8.9 μg/dose

Group 4 - mRNA-1647 89 μg/dose

	Summary	α1-acid Glycoprotein	α2-macroglobulin	
Groun	Information	· -	μg/mL sight and the second se	
Group	Illioilliation	μg/mL		
1	Mean	72.220	42.357 adjica 13	
_	SD	24.521	20.773	
	N	10	102.00	
			1108; 15at 01/2	
2	Mean	235.634 C	55.994	
	SD	52.630	15,029	
	N	10	0,010	
	% Diff (G1)	226	32	
			all all	
3	Mean	339.454 C	123.631 E	
	SD	50.928	113.492	
	N	10	10	
	% Diff (G1)	370	192	
		SULINO		
4	Mean	505.421 C	186.357 E	
	SD	137,000	249.663	
	N	10	10	
	% Diff (G1)	600	340	
		20		

Significantly different from control group (Group 1) value: $A - P \le 0.05 \ B - P \le 0.01 \ C - P \le 0.001$ (Dunnett) $D - P \le 0.05 \ E - P \le 0.01 \ F - P \le 0.001 \ (Dunn)$

Table 9 Summary of a1-acid Glycoprotein and a2-macroglobulin Values

Day 57 Males

Group 1 - Reference Item

Group 3 - mRNA-1647 27 μg/dose

Group 2 - mRNA-1647 8.9 μg/dose

	Summary	α1-acid Glycoprotein	α2-macroglobulin μg/mL 20.773 4.717 37.996 a 12.667 5 83	
Group	Information	μg/mL	μg/mL	
1	Mean	88.440	20.773	
	SD	8.092	4.717	
	N	4	0. 1/10,000	
			110 tisio 101 h	
4	Mean	87.166	37.996 a	
	SD	12.415	12.667	
	N	5		
	% Diff (G1)	-1	83	
		SUPPORT	$d - P \le 0.05 \text{ e} - P \le 0.01 \text{ f} - P \le 0.001 \text{ (Wilcoxon)}$	
		ot be Ised to support	d-P≥0.05 e-P≤0.01 f-P≤0.001 (Wilcoxon)	
	cument	cannot be used to support	37.996 a 12.667 5 83 E: $a - P \le 0.05 \text{ b} - P \le 0.01 \text{ c} - P \le 0.001 \text{ (}t\text{-test)}$ $d - P \ge 0.05 \text{ e} - P \le 0.01 \text{ f} - P \le 0.001 \text{ (Wilcoxon)}$	

Table 9 Summary of a1-acid Glycoprotein and a2-macroglobulin Values

Day 57 Females

Group 1 - Reference Item

Group 3 - mRNA-1647 27 μg/dose

Group 2 - mRNA-1647 8.9 μg/dose

	Summary	α1-acid Glycoprotein	α2-macroglobulin μg/mL 35.152 13.723 54.802 38.529 5 56	
Group	Information	μg/mL	μg/mL	
			1100 N3	
1	Mean	68.932	35.152	
	SD	4.834	13.723	
	N	5	3. 2/10, 100	
			1104,150,191	
4	Mean	75.622	.54,802	
	SD	10.977	38.529	
	N	5		
	% Diff (G1)	10	56	
			all on	
Significa	antly different from	control group (Group 1) value	a: $a - P \le 0.05$ b $- P \le 0.01$ c $- P \le 0.001$ (t-test) d $- P \le 0.05$ e $- P \le 0.01$ f $- P \le 0.001$ (Wilcoxon)	
Significa	antly different from	control group (Group 1) value	$\begin{array}{c} 54.802 \\ 38.529 \\ 56 \\ \\ \text{aP} \le 0.05 \text{ bP} \le 0.01 \text{ cP} \le 0.001 \text{ (}t\text{-test)} \\ \text{dP} \ge 0.05 \text{ eP} \le 0.01 \text{ fP} \le 0.001 \text{ (Wilcoxon)} \end{array}$	

Table 10 **Summary of Cytokine Values**

IL-1 β (pg/mL) Males

Group 1 - Reference Item

	Summary			Day	NO.	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 4	3 - 6 h Post Dose	5′
				atio, Sex		
1	Mean	81.768	21.700	59.374	124.482	51.91
	SD	151.835	24.183	88.301	265.269	92.12
	N	4	5	5	5	4
			200	59.374 88.301 5 58.726 80.621 5		
4	Mean	58.354	44.110	58.726	39.250	15.06
	SD	52.019	36.995	80.621	48.320	20.612
	N	5	BU 312 40	5	5	:
	% Diff (G1)	-29	103	-1	-68	-7
			To. K			
		iopor	6-1-3003 6-1-30.01	- 1 _ 0.001 (
		not be used to support	44.110 36.995 103 He: $a - P \le 0.05$ b $- P \le 0.01$ d $- P \le 0.05$ e $- P \le 0.01$			

Table 10 **Summary of Cytokine Values**

IL-6 (pg/mL) Males

Group 1 - Reference Item

	Summary			Day	Up	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 43	3 - 6 h Post Dose	57
				atio, esp		
1	Mean	176.000	176.000	176.000	176.000	176.000
	SD	0.000	0.000	0.000	0.000	0.000
	N	4	5	29 - 6 h Post Dose 4. 176.000 0.000 5 176.000 0.000 5 01 c - P \leq 0.001 (t-test)	5	4
		4=4000	1-1000	cation 20	4=4000	4=4.000
4	Mean	176.000	176.000	176.000	176.000	176.000
	SD	0.000	0.000	0.000	0.000	0.000
	N	5	01, 0,2 4	5	5	5
	% Diff (G1)	0	ding of	0	0	0
		2	100 C-1 30.	or 1-1 30.001 (wheeker)		
	ournant car	not be used to support	der Redy C-1 So.	176.000 0.000 5 0 01 $c - P \le 0.001$ (t-test) 01 $f - P \le 0.001$ (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

TNF- α (pg/mL) Males

Group 1 - Reference Item

	Summary			Day	(O	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 43	3 - 6 h Post Dose	5′
				ijo, cek		
1	Mean	1.470	2.534	1.470	2.450	3.09
	SD	0.000	2.379	0.000	2.191	3.25
	N	4	5	29 - 6 h Post Dose 43 0.000 5 1.470 0.000 5 0	5	4
				110,000		
4	Mean	1.470	3.648	1.470	3.746	1.47
	SD	0.000	3.010	0.000	3.170	0.00
	N	5	en 315 40	5	5	:
	% Diff (G1)	0	xi(10) 44)	0	53	-5:
			No. K			
		, ippor	d-P≤0.05 e-P≤0.01	f - P ≤ 0.001 (Wilcoxon)		
		not be used to support	3.648 3.010 5 44 ae: $a - P \le 0.05 \ b - P \le 0.01$ $d - P \le 0.05 \ e - P \le 0.01$	f - P ≤ 0.001 (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

IP-10 (pg/mL) Males

Group 1 - Reference Item

	Summary			Day		
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose	43 - 6 h Post Dose	5
				. 0, 6,4		
1	Mean	119.183	81.600	108.196	114.608	111.97
	SD	55.636	18.170	42.739	70.494	79.73
	N	4	18.170 5 882.356 d 311.841	993.816 b 523.188 5	5	
			, Q'a'	3110 1200		
4	Mean	1215.712 b	882.356 d	993.816 b	667.464 c	70.60
	SD	481.589	311.841	523.188	176.698	19.92
	N	5	OL, 02, 40	5	5	:
	% Diff (G1)	920	981	819	482	-3
			Yer K			
Significa	ntly different from co	ontrol group (Group 1) va	lue: $a - P \le 0.05$ $b - P \le 0.0$ $d - P \le 0.05$ $e - P \le 0.0$	1 c - P ≤ 0.001 (<i>t</i> -test) 1 f - P ≤ 0.001 (Wilcoxon)		
Significa	ntly different from co	ontrol group (Group 1) va	lue: $a - P \le 0.05$ $b - P \le 0.0$ $d - P \le 0.05$ $e - P \le 0.0$	993.816 b 523.188 5 819 1 c-P≤0.001 (t-test) 1 f-P≤0.001 (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

MIP-1- α (pg/mL) Males

Group 1 - Reference Item

				. 0 .		
	Summary			Day	D	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 43	3 - 6 h Post Dose	5
				atio, 20th		
1	Mean	5.850	5.850	5.850	5.850	5.85
	SD	0.000	0.000	0.000	0.000	0.00
	N	4	5	5.850 0.000 5 5.850 0.000 5 0	5	•
			000	atio 200		
4	Mean	5.850	9.986	5.850	5.850	5.85
	SD	0.000	9.248	0.000	0.000	0.00
	N	5	6/1/201/70	5	5	;
	% Diff (G1)	0	in 71	0	0	1
			16, K			
		. 100	Set ,			
	a di Co	inothe used to supply	nde ^t	5.850 0.000 5 0 01 c-P \leq 0.001 (t-test) 01 f-P \leq 0.001 (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

MCP-1 (pg/mL) Males

Group 1 - Reference Item

	Summary			Day	NO.	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose	43 - 6 h Post Dose	57
				*10, COX		
1	Mean	385.368	407.454	387.200	352.102	209.503
	SD	84.450	64.383	87.399	29.006	161.154
	N	4	649.598 337.498	387.200 87.399 5 563.292 151.572 5	5	4
4	Mean	531.784	649.598	563.292	484.526	166.148
	SD	127.495	337,498	151.572	283.312	130.973
	N	5	allie april	5	5	5
	% Diff (G1)	38	59	45	38	-21
			Yer K			
		,,199	of Reduced			
		not be used to supply	649.598 337.498 59 alue: $a - P \le 0.05$ b $- P \le 0.0$ d $- P \le 0.05$ e $- P \le 0.0$			

Table 10 **Summary of Cytokine Values**

IL-1 β (pg/mL) Females

Group 1 - Reference Item

	~				~ 0 .	
_	Summary	4 44 5 5	4.5 44.5 5	Day	3 - 6 h Post Dose	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 43	5 - 6 h Post Dose	5′
				alio so		
1	Mean	81.260	81.770	24.666	51.744	14.792
	SD	67.051	93.939	29.166	52.373	12.313
	N	4	25.974 44.999	24.666 29.166 5 15.594 21.788 5	5	4
			.000	2110/200		
4	Mean	25.924	25.974	15.594	23.160	9.680
	SD	44.887	44.999	21.788	38.706	8.56
	N	5	OL, 32, 40	5	5	:
	% Diff (G1)	-68	-68	-37	-55	-3:
Significa	ntly different from c	ontrol group (Group 1) va	llue: $a - P \le 0.05 b - P \le 0.05$	$0.01 \text{ c} - P \le 0.001 \text{ (}t\text{-test)}$		
		SUPP	del			
	S	amot be leged to sed i		15.594 21.788 5 -37 01 c-P \leq 0.001 (t-test) 01 f-P \leq 0.001 (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

IL-6 (pg/mL) Females

Group 1 - Reference Item

	Summary			Day	No.	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose	3 - 6 h Post Dose	57
				atilo So,		
1	Mean	176.000	176.000	176.000	176.000	176.000
	SD	0.000	0.000	0.000	0.000	0.000
	N	4	5	5	5	4
		4=4.000	1-1000	allo	474.000	4=4004
4	Mean	176.000	176.000	176.000	176.000	176.000
	SD	0.000	0.000	0.000	0.000	0.000
	N	5	61, 32 40	5	5	5
	% Diff (G1)	0	dillo 0	0	0	(
Significa	ntly different from co	ontrol group (Group 1) va	lue: $a - P \le 0.05$ b $- P \le 0.01$ d $- P \le 0.05$ e $- P \le 0.01$	29 - 6 h Post Dose 176.000 0.000 5 176.000 0.000 5 0 $c - P \le 0.001 \ (t\text{-test})$ $f - P \le 0.001 \ (Wilcoxon)$		
Significa	ntly different from co	ontrol group (Group 1) va	176.000 0.000 $0.$	$c - P \le 0.001$ (t-test) $f - P \le 0.001$ (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

TNF- α (pg/mL) Females

Group 1 - Reference Item

				.		
	Summary			Day	- 6 h Post Dose	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 43	- 6 h Post Dose	5
				atio. Ser		
1	Mean	1.470	2.790	(1.470)	1.470	3.68
	SD	0.000	2.952	0,000	0.000	3.03
	N	4	5	3.996 3.459 5 172	5	
			20°	atile 200		
4	Mean	1.470	4.792	3.996	2.544	1.47
	SD	0.000	4.765	3.459	2.402	0.00
	N	5	Elle 37, 70	5	5	
	% Diff (G1)	0	72	172	73	-6
			No. K			
		,08	Set Cos			
		annot be used to supply	nder Res	3.996 3.459 5 172 01 $c - P \le 0.001$ (t-test) 01 $f - P \le 0.001$ (Wilcoxon)		

Table 10 **Summary of Cytokine Values**

IP-10 (pg/mL) Females

Group 1 - Reference Item

	Summary			Day	200	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose 2	9 - 6 h Post Dose	43 - 6 h Post Dose	57
Gloup	mormation	1 - 0 11 1 05t 12050	13 - 0 11 1 05t D05C 2	J - O II I OSt DOSC	+3 - 0 II I OSt DOSC	31
1	Mean	101.380	78.686	75.830	105.752	52.852
•	SD	45.097	30 456	30 099	35.779	18.137
	N	4	5	5	5	5
			1254.524 c 241,636	5 1374.798 d 414.653		
4	Mean	1484.720 d	1254.524 c	1374.798 d	947.402 d	47.134
	SD	308.884	241,636	414.653	333.750	13.418
	N	5	50 30 40	5	5	5
	% Diff (G1)	1365	1494	1713	796	-11
Significa	ntly different from c	ontrol group (Group 1) va	alue: $a - P \le 0.05$ b $- P \le 0.01$ d $- P \le 0.05$ e $- P \le 0.01$	c - P \leq 0.001 (<i>t</i> -test) f - P \leq 0.001 (Wilcoxo	n)	
Significa	ntly different from c	ontrol group (Group 1) va	1254.524 c 241.636 494 $alue: a - P \le 0.05 \text{ b} - P \le 0.01$ $d - P \le 0.05 \text{ e} - P \le 0.01$	$c - P \le 0.001$ (<i>t</i> -test) $f - P \le 0.001$ (Wilcoxo	n)	

Table 10 **Summary of Cytokine Values**

MIP-1- α (pg/mL) Females

Group 1 - Reference Item

	Summary			Day	Up.	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 2	3 - 6 h Post Dose	57
				ijo, cek		
1	Mean	5.850	5.850	(5.850)	5.850	5.850
	SD	0.000	0.000	0.000	0.000	0.000
	N	4	25.098 18.462	24.632 17.515 5	5	5
			000	31101200		
4	Mean	20.474	25.098	24.632	10.984	5.850
	SD	13.535	18,462	17.515	11.480	0.000
	N	5	18,462	5	5	5
	% Diff (G1)	250	329	321	88	0
Cimicina	.1 1'00 .0		7 7 7			
Significa	ntly different from c	ontrol group (Group 1) va	alue: $a - P \le 0.05$ b $- P \le 0.01$ d $- P \le 0.05$ e $- P \le 0.01$	c - P \leq 0.001 (<i>t</i> -test) f - P \leq 0.001 (Wilcoxon)		
Significa	ntly different from c	control group (Group 1) value of the state o	$ \begin{array}{c} 25.098 \\ 18.462 \\ 329 \end{array} $ Talue: $a - P \le 0.05, b - P \le 0.01, b $	$c - P \le 0.001 (t\text{-test})$ $f - P \le 0.001 (Wilcoxon)$		

Table 10 **Summary of Cytokine Values**

MCP-1 (pg/mL) Females

Group 1 - Reference Item

					VO	
	Summary			Day	Up	
Group	Information	1 - 6 h Post Dose	15 - 6 h Post Dose	29 - 6 h Post Dose 4	3 - 6 h Post Dose	5′
				tio ser		
1	Mean	128.680	158.156	174.606	169.772	113.61
	SD	116.360	120.028	143,082	136.358	96.40
	N	4	5	3 (1)	5	:
			26g.	1032.040 b 408.110 5		
4	Mean	525.168 a	1032.490 a	1032.040 Ъ	397.324	132.25
	SD	272.356	668.447	408.110	461.595	138.09
	N	5	ELL 31 40	5	5	;
	% Diff (G1)	308	553	491	134	1
			$d - P \le 0.05 e - P \le 0.0$	$01 \text{ f} - P \le 0.001 \text{ (Wilcoxon)}$		
		SUPP	d-P≤0.05 e-P≤0.0	01 f-P≤0.001 (Wilcoxon)		
		the leed to supply	d-P≤0.05 e-P≤0.0	1032.040 b 408.110 5 491 01 c-P≤0.001 (t-test) 01 f-P≤0.001 (Wilcoxon)		